LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS

Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis and stimulating immune responses in patients are disclosed. The compounds provided include polypeptides that contain at least an immunogenic portion of one or more Leishmania antigens, or a variant thereof. Vaccines and pharmaceutical compositions comprising such polypeptides are also provided and may be used, for example, for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmania infection.

Description: Description LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS Technical Field The present invention relates generally to compositions and methods for preventing, treating and detecting leishmaniasis. and for stimulating immune responses in patients. The invention is more particularly related to polypeptides comprising an immunogenic portion of a Leishmania antigen or a variant thereof, and to vaccines and pharmaceutical compositions comprising one or more such polypeptides. The vaccines and pharmaceutical compositions may be used, for example, for the prevention and therapy of leishmaniasis. as well as for the detection of Leishmania infection in patients and blood supplies. Background of the Invention Leishmania organisms are intracellular protozoan parasites of macrophages that cause a wide range of clinical diseases in humans and other animals, primarily dogs, ln some infections, the parasite may lie dormant for many years. In other cases, the host may develop one of a variety of forms of leishmaniasis. For example, the disease may be asymptomatic or may be manifested as subclinical visceral leishmaniasis, which is characterized by mild symptoms of malaise, diarrhea and intermittent hepatomegaly. Patients with subclinical or asymptomatic disease usually have low antibody titers, making the disease difficult to detect with standard techniques. Alternatively, leishmaniasis may be manifested as a cutaneous disease. which is a severe medical problem but is generally self-limiting, or as a highly destructive mucosal disease, which is not self-limiting. Finally, and most seriously, the disease may be manifested as an acute visceral infection involving the spleen, liver and lymph nodes, which, untreated, is generally a fatal disease. Symptoms of acute visceral leishmaniasis include hepatosplenomegaly, fever, leukopenia, anemia and hypergammaglobulinemia. Leishmaniasis is a serious problem in much of the world, including Brazil. China. East Africa, India and areas of the Middle East. The disease is also endemic in the Mediterranean region, including southern France, Italy, Greece, Spain, Portugal and North Africa. The number of cases of leishmaniasis has increased dramatically in the last 20 years, and millions of cases of this disease now exist worldwide. About 2 million new cases are diagnosed each year, 25% of which are visceral leishmaniasis. There are, however, no vaccines or effective treatments currently available. Accurate diagnosis of leishmaniasis is also frequently difficult to achieve. There are 20 species of Leishmania that infect humans, including L. donovani. L. chagasi, L. infantum, L. major, L. amazonensis, L braziliensis, L. panamensis, L. tropica, and L. guyanensis, and there are no distinctive signs or symptoms that unambiguously indicate the presence of Leishmania infection. Parasite detection methods have been used, but such methods are not sensitive or practical. Current serological tests (using, for example, ELISA or immunofiuorescence techniques) and skin tests typically use whole or lysed parasites. Such tests are generally insensitive, irreproducible and prone to cross-reaction with a variety of other diseases. In addition, the preparations employed in such tests are often unstable. Accordingly, there is a need in the art for vaccines to prevent leishmaniasis in humans and dogs, and for improved therapeutic compositions for the treatment of leishmaniasis. There is also a need for improved methods of detecting Leishmania infection in patients and in blood supplies. The present invention fulfills these needs and further provides other related advantages. Summary of the Invention Briefly stated, the present invention provides compositions and methods for preventing, treating and detecting leishmaniasis, as well as for stimulating immune responses in patients. In one aspect, polypeptides are provided, comprising at least an immunogenic portion of a Leishmania antigen, or a variant of such an antigen that differs only in conservative substitutions and/or modifications. In one embodiment of this aspect, the Leishmania antigen has the amino acid sequence recited in SEQ ID NO:2. In another embodiment, the Leishmania antigen has the amino acid sequence recited in SEQ ID NO:4. DNA sequences encoding the above polypeptides, recombinant expression vectors comprising these DNA sequences and host cells transformed or transfected with such expression vectors are also provided. In related aspects, the present invention provides pharmaceutical compositions which comprise at least an immunogenic portion of a Leishmania antigen (or a variant of such an antigen that differs only in conservative substitutions and/or modifications) as described herein and a physiologically acceptable carrier. In addition, vaccines which comprise at least an immunogenic portion of a Leishmania antigen (or a variant of such an antigen that differs only in conservative substitutions and/or modifications) as described herein and a non-specific immune response enhancer are also provided. In one embodiment of these aspects, the Leishmania antigen has the amino acid sequence recited in SEQ ID NO:2. In another embodiment, the Leishmania antigen has the amino acid sequence recited in SEQ ID NO:4. In still further related embodiments, the pharmaceutical compositions and vaccines comprise at least two different polypeptides selected from the group consisting of: (a) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:2, or a variant of such an antigen that differs only in conservative substitutions and/or modifications; (b) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:4, or a variant of such an antigen that differs only in conservative substitutions and/or modifications; (c) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:6, or a variant of said antigen that differs only in conservative substitutions and/or modifications; (d) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:8, or a variant of said antigen that differs only in conservative substitutions and/or modifications; and (e) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO: 10, or a variant of said antigen that differs only in conservative substitutions and/or modifications. In other related embodiments, the pharmaceutical compositions and vaccines comprise soluble Leishmania antigens. In another aspect, the present invention provides methods for inducing protective immunity against leishmaniasis in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above. In further aspects, methods and diagnostic kits are provided for detecting Leishmania infection in a patient. The methods comprise: (a) contacting dermal cells of a patient with a pharmaceutical composition as described above; and (b) detecting an immune response on the patient's skin, and therefrom detecting Leishmania infection in the patient. The diagnostic kits comprise: (a) a pharmaceutical composition as described above; and (b) an apparatus sufficient to contact the pharmaceutical composition with the dermal cells of a patient. In further aspects, the present invention provides methods for stimulating a cellular and/or humoral immune response in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above. In a related aspect, methods are provided for treating a patient afflicted with a disease responsive to IL-12 stimulation, comprising administering to a patient a pharmaceutical composition or vaccine as described above. These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. Al' references disclosed herein are hereby incoφorated by reference in their entirety as if each was incorporated individually. Brief Description ofthe Drawings Figure 1 shows the stimulation of proliferation of T-cells obtained from L. riøHøvαw ' -imrnunized BALB/c mice (represented by stimulation index) by L donovani-infected macrophages after incubation for 24. 48 and 72 hours. Figure 2 illustrates representative HPLC profiles of peptides isolated from MHC class II molecules of P388D1 macrophages. Panel A shows peptides isolated from uninfected macrophages and panel B shows peptides isolated from L. donovani infected macrophages. The arrows in panel B indicate peptide peaks present only in the infected macrophage preparation. Figure 3 illustrates the expression and purification of Ldp23 as a recombinant fusion protein. Panel A shows a Coomassie blue-stained SDS-PAGE gel of lysed E. coli without (lane 1 ) and with (lane 2) IPTG induction of Ldp23 expression. Arrow indicates the recombinant fusion protein. Panel B shows the fusion protein following excision from a preparative SDS-PAGE gel, electroelution, dialysis against PBS and analytical SDS-PAGE. Figure 4 presents a Northern blot analysis of total RNA prepared from L. donovani, L. major, L. amazonensis and L. pifanoi with a 32 P labeled Ldp23 gene. 1 , 2 and 3 refer to RNA obtained from promastigotes at the logarithmic growth phase, promastigotes at the stationary growth phase and amastigote forms, respectively. Figure 5 shows a Western blot analysis of L. donovani promastigote antigens incubated with pre-immune rabbit serum (lane A) or with anti-Ldp23 rabbit antiserum (lane B). Figure 6 illustrates the surface expression of Ldp23 on live L. donovani promastigotes. The dotted line shows the indirect immunofiuorescence performed using pre-immune mouse serum and the solid line shows the result obtained with mouse anti-GST-Ldp23 antiserum. Fluorescence intensity was analyzed by FACScan. Figure 7 shows the stimulation of Leishmania-specific T-cell proliferation by Ldp23. The results are presented as relative cell number as a function of fluorescence intensity. T-cells (lOVwell) were purified from lymph nodes of BALB/c mice immunized in the foot pad with L. donovani promastigotes in CFA and were cultured with various concentrations of the purified recombinant Ldp23 in the presence of 2 x 10 5 Mitomycin C-treated normal BALB/c spleen mononuclear cells. Proliferation of T-cells was measured at 27 hours of culture. Values are expressed as cpm and represent the mean of [ 3 H]TdR incoφoration of triplicate cultures. Figure 8 illustrates the Ldp23-induced cytokine production by lymph node cells of BALB/c mice. Cultures were incubated with varying amounts of Ldp23 or Leishmania lysate, presented as μg/mL, and were assayed by ELISA for the production of interferon-γ (panel A) or interleukin-4 (panel B), both of which are shown as ng/mL. Figure 9 shows the PCR amplification of cytokine mRNAs isolated from ML (Panel A) and CL (panel B) patient PBMC before and after stimulation with representative polypeptides of the present invention. Lanes O and - indicate the level of PCR products at the initiation of culture and after 72 hours of culture, respectively, in the absence of added polypeptide; lanes Lb, 83a and 83b indicate the level of PCR products following culturing of PBMC with L. braziliensis lysate, Lbhsp83a and Lbhsp83b, respectively. Figure 10 presents a comparison of the levels of interferon-γ (panel A) and TNF-α (panel B) in the supematants of 72 hour PBMC cultures from Leishmania- infected and control individuals in response to stimulation with parasite lysate or the indicated polypeptides. Figure 1 1 illustrates the levels of IL-10 p40 (in pg/mL) in the supernatant of PBMC cultures from L. bra∑iliensis- ' fccted individuals and uninfected controls 72 hours following stimulation with parasite promastigote lysate (Lb), Lbhsp83a or Lbhsp83b. Figure 12 presents the reactivities of L. braziliensis infection sera from patients with representative polypeptides of the present invention in a standard ELISA. Values are expressed as absorbance at 405 nm. Figures 13A and 13B, illustrates the level of secreted IL-4 and IFN-γ (in pg/mL) stimulated in mouse lymph node cultures by the addition of representative polypeptides ofthe present invention. Figure 14 shows the level of IFN-γ (in pg/mL) secreted by Leishmania- infected and uninfected human PBMC stimulated by Ml 5, as compared to the levels stimulated by L. major lysate and L-Rack, an antigen that does not appear to be recognized by Leishmania-infected humans. Figure 15 shows the level of IFN-γ (in pg/mL) secreted by infected and uninfected human PBMC stimulated by soluble Leishmania antigens (S antigens), as compared to the levels stimulated by L. major lysate and L-Rack. Figure 16 illustrates the proliferation of murine lymph node cultures stimulated by the addition of representative polypeptides of the present invention. Values are expressed as cpm. Figure 17 shows the proliferation of human PBMC, prepared from Leishmania-i munc and uninfected individuals, stimulated by Ml 5 as compared to the proliferation stimulated by L. major lysate and L-Rack. Values are expressed as cpm. Figure 18 illustrates the proliferation of human PBMC, prepared from infected and uninfected individuals, stimulated by soluble Leishmania antigens as compared to the proliferation stimulated by culture medium, L. major lysate and L- Rack. Values are expressed as cpm. Figure 19 presents a comparison of a Lbhsp83 sequence with homologous sequences from L amazonensis (Lahsp83), T. cruzi (Tchsp83) and humans (Huhsp89). Detailed Description ofthe Invention As noted above, the present invention is generally directed to compositions and methods for preventing, treating and detecting leishmaniasis, as well as for stimulating immune responses in patients. The compositions of the subject invention include polypeptides that comprise at least an immunogenic portion of a Leishmania antigen, or a variant of such an antigen that differs only in conservative substitutions and/or modifications. In one preferred embodiment, compositions of the present invention include multiple polypeptides selected so as to provide enhanced protection against a variety of Leishmania species. Polypeptides within the scope of the present invention include, but are not limited to, polypeptides comprising immunogenic portions of Leishmania antigens having the sequences recited in SEQ ID NO:2 (referred to herein as Ml 5), SEQ ID NO:4 (referred to herein as Ldp23), SEQ ID NO:6 (referred to herein as Lbhsp83), SEQ ID NO:8 (referred to herein as Lt-210) and SEQ ID NO: 10 (referred to herein as LbeIF4A). As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent bonds. Thus, a polypeptide comprising an immunogenic portion of one of the above antigens may consist entirely of the immunogenic portion, or may contain additional sequences. The additional sequences may be derived from the native Leishmania antigen or may be heterologous, and such sequences may (but need not) be immunogenic. An antigen "having' " a particular sequence is an antigen that contains, within its full length sequence, the recited sequence. The native antigen may. or may not. contain additional amino acid sequence. An immunogenic portion of a Leishmania antigen is a portion that is capable of eliciting an immune response (i.e., cellular and/or humoral) in a presently or previously Leishmania-inkcted patient (such as a human or a dog) and/or in cultures of lymph node cells or peripheral blood mononuclear cells (PBMC) isolated from presently or previously Leishmania-m ' kcted individuals. The cells in which a response is elicited may comprise a mixture of cell types or may contain isolated component cells (including, but not limited to, T-cells, NK cells, macrophages, monocytes and/or B cells). In particular, immunogenic portions are capable of inducing T-cell proliferation and/or a dominantly Thi -type cytokine response (e.g., IL-2, IFN-γ, and/or TNF-α production by T-cells and or NK cells; and/or IL-12 production by monocytes, macrophages and or B cells). Immunogenic portions of the antigens described herein may generally be identified using techniques known to those of ordinary skill in the art, such as the representative methods provided herein. The compositions and methods of the present invention also encompass variants of the above polypeptides. A "variant," as used herein, is a polypeptide that differs from the native antigen only in conservative substitutions and/or modifications, such that the ability ofthe polypeptide to induce an immune response is retained. Such variants may generally be identified by modifying one of the above polypeptide sequences and evaluating the immunogenic properties of the modified polypeptide using, for example, the representative procedures described herein. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1 ) ala, pro, gly, glu, asp, gin, asn. ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu. met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, tφ, his. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N- terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His). or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region. "Polypeptides" as described herein also include combination polypeptides. A "combination polypeptide" is a polypeptide comprising at least one of the above immunogenic portions and one or more additional immunogenic Leishmania sequences, which are joined via a peptide linkage into a single amino acid chain. The sequences may be joined directly (i.e., with no intervening amino acids) or may be joined by way of a linker sequence (e.g., Gly-Cys-Gly) that does not significantly diminish the immunogenic properties ofthe component polypeptides. In general, Leishmania antigens having immunogenic properties, and DNA sequences encoding such antigens, may be prepared using any of a variety of procedures from one or more Leishmania species including, but not limited to, L. donovani. L. chagasi. L. infantum, L. major, L. amazonensis, L. braziliensis, L. panamensis. L. tropica, and L. guyanensis. Such species are available, for example, from ATCC, Rockville. MD. For example, peptides isolated from MHC class II molecules of macrophages infected with a Leishmania species may be used to rescue the corresponding Leishmania donor antigens. MHC class II molecules are expressed mainly by cells of the immune system, including macrophages. These molecules present peptides, which are usually 13-17 amino acids long, derived from foreign antigens that are degraded in cellular vesicles. The bound peptide antigens are then recognized by CD4 T-cells. Accordingly, foreign peptides isolated from MHC class II molecules of. for example, Leishmania-infected murine macrophages may be used to identify immunogenic Leishmania proteins. Briefly, peptides derived from Leishmania antigens may be isolated by comparing the reverse phase HPLC profile of peptides extracted from infected macrophages with the profile of peptides extracted from uninfected cells. Peptides giving rise to distinct HPLC peaks unique to infected macrophages may then be sequenced using, for example, Edman chemistry as described in Edman and Berg, Eur J. Biochem. SO: 1 16-132 ( 1967). A DNA fragment corresponding to a portion of a Leishmania gene encoding the peptide may then be amplified from a Leishmania cDNA library using an oligonucleotide sense primer derived from the peptide sequence and an oligo dT antisense primer. The resulting DNA fragment may then be used as a probe to screen a Leishmania library for a full length cDNA or genomic clone that encodes the Leishmania antigen. Such screens may generally be performed using techniques well known to those of ordinary skill in the art, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1989). This approach may be used to identify a 23 kD Leishmania donovani antigen (referred to herein as Ldp23). The sequence of a DNA molecule encoding Ldp23 is provided in SEQ ID NO:3 and the amino acid sequence of Ldp23 is provided in SEQ ID NO:4. Using the methods described herein, Ldp23 has been shown to induce a Thi immune response in T-cells prepared from Leishmania-infected mice. Alternatively, a Leishmania cDNA or genomic expression library may be screened with serum from a Leishmania-infected individual, using techniques well known to those of ordinary skill in the art. DNA molecules encoding reactive antigens may then be used to express the recombinant antigen for purification. The immunogenic properties of the purified Leishmania antigens may then be evaluated using, for example the representative methods described herein. For example, sera from Leishmania-infected mice may be used to screen a cDNA library prepared from Leishmania amastigotes. Reactive clones may then be expressed and recombinant proteins assayed for the ability to stimulate T-cells or NK cells derived from Leishmania-im ne individuals (i.e., individuals having evidence of infection, as documented by positive serological reactivity with Leishmania-specific antibodies and/or a Leishmania-specific DTH response, without clinical symptoms of leishmaniasis). This procedure may be used to obtain a recombinant DNA molecule encoding the Leishmania antigen designated Ml 5. The sequence of such a DNA molecule is provided in SEQ ID NO: l , and the amino acid sequence of the encoded protein is provided in SEQ ID NO:2. A similar approach may be used to isolate a genomic DNA molecule encoding an immunogenic Leishmania braziliensis antigen, referred to herein as Lbhsp83. More specifically, a genomic clone encoding Lbhsp83 may be isolated by screening a L. braziliensis expression library with sera from a Leishmania-infected individual. The DNA encoding Lbhsp83 is homologous to the gene encoding the eukaryotic 83 kD heat shock protein. The sequence of a DNA molecule encoding nearly all of Lbhsp83 is presented in SEQ ID NO:5, and the encoded amino acid sequence is provided in SEQ ID NO:6. Using the methods described below, Lbhsp83 has been found to stimulate proliferation, and a mixed Thi and Th2 cytokine profile, in PBMC isolated from L braziliensis-infected patients. Accordingly, Lbhsp83 is an immunogenic Leishmania antigen. Regions of Lbhsp83 that are not conserved with the mammalian gene have been found to be particularly potent for T-cell stimulation and antibody binding. Such regions may be identified, for example, by visual inspection of the sequence comparison provided in Figure 19. This approach may also be used to isolate a DNA molecule encoding a 210 kD immunogenic L. tropica antigen, referred to herein as Lt-210. The preparation and characterization of Lt-210, and immunogenic portions thereof (such as Lt-1 and immunogenic repeat and non-repeat sequences), is described in detail in U.S. Patent Application Serial No. 08/51 1,872, filed August 4, 1995. The sequence of a DNA molecule encoding Lt-1 is provided in SEQ ID NO:7 and the encoded amino acid sequence is presented in SEQ ID NO:8. The above approach may further be used to isolate a DNA molecule encoding a L. braziliensis antigen referred to herein as LbeIF4A. Briefly, such a clone may be isolated by screening a L. braziliensis expression library with sera obtained from a patient afflicted with mucosal leishmaniasis, and analyzing the reactive antigens for the ability to stimulate proliferative responses and preferential Thi cytokine production in PBMC isolated from Leishmania-infected patients, as described below. The preparation and characterization of LbeIF4A is described in detail in U.S. Patent Application Serial Nos. 08/454,036 and 08/488,386, which are continuations-in-part of U.S. Patent Application Serial No. 08/232,534, filed April 22, 1994. The sequence of a DNA molecule encoding LbeIF4A is provided in SEQ ID NO:9 and the encoded amino acid sequence is presented in SEQ ID NO: 10. Homologs of LbeIF4A, such as that found in L. major, may also be isolated using this approach, and are within the scope of the present invention. Compositions ofthe present invention may also, or altematively. contain soluble Leishmania antigens. As used herein. "soluble Leishmania antigens " ' refers to a mixture of at least 8 different Leishmania antigens that may be isolated from the supematant of Leishmania promastigotes of any species grown for 8-12 hours in protein-free medium. Briefly, the organisms are grown to late log phase in complex medium with serum until they reach a density of 2-3 x 10 7 viable organisms per mL of medium. The organisms are thoroughly washed to remove medium components and resuspended at 2-3 x 10 7 viable organisms per mL of defined serum-free medium consisting of equal parts RPMI 1640 and medium 199, both from Gibco BRL, Gaithersburg. MD. After 8-12 hours, the supematant containing soluble Leishmania antigens is removed, concentrated 10 fold and dialyzed against phosphate-buffered saline for 24 hours. The presence of at least eight different antigens within the mixture of Leishmania antigens may be confirmed using SDS-PAGE (i.e., through the observation of at least 8 different bands). The immunogenic properties of the soluble Leishmania antigens may be confirmed by evaluating the ability of the preparation to elicit an immune response in cultures of lymph node cells and/or peripheral blood mononuclear cells (PBMC) isolated from presently oi previously Leishmania-infected individuals. Such an evaluation may be performed as described below. Regardless of the method of preparation, the antigens described herein are immunogenic. In other words, the antigens (and immunogenic portions thereof) are capable of eliciting an immune response in cultures of lymph node cells and/or peripheral blood mononuclear cells (PBMC) isolated from presently or previously Leishmania-infected individuals. More specifically, the antigens, and immunogenic portions thereof, have the ability to induce T-cell proliferation and/or to elicit a dominantly Thi -type cytokine response (e.g., IL-2, IFN-γ, and/or TNF-α production by T-cells and/or NK cells; and/or IL-12 production by monocytes, macrophages and/or B cells) in cells isolated from presently or previously Leishmania-infected individuals. A Leishmania-infected individual may be afflicted with a form of leishmaniasis (such as subclinical, cutaneous, mucosal or active visceral) or may be asymptomatic. Such individuals may be identified using methods known to those of ordinary skill in the art. Individuals with leishmaniasis may be identified based on clinical findings associated with at least one ofthe following: isolation of parasite from lesions, a positive skin test with Leishmania lysate or a positive serological test. Asymptomatic individuals are infected individuals who have no signs or symptoms of the disease, but such individuals can be identified based on a positive serological test and/or skin test with Leishmania lysate. The term "PBMC," which refers to a preparation of nucleated cells that are present in peripheral blood, encompasses both mixtures of cells and preparations of one or more purified cell types. PBMC may be isolated by methods known to those in the art. For example, PBMC may be isolated by density centrifugation through, for example, Ficoll™ (Winthrop Laboratories, New York). Lymph node cultures may generally be prepared by immunizing BALB/c mice (e.g., in the rear foot pad) with Leishmania promastigotes emulsified in complete Freund's adjuvant. The draining lymph nodes may be excised following immunization and T-cells may be purified in an anti-mouse Ig column to remove the B cells, followed by a passage through a Sephadex G10 column to remove the macrophages. Similarly, lymph node cells may be isolated from a human following biopsy or surgical removal of a lymph node. The ability of a polypeptide (e.g., a Leishmania antigen or a portion or other variant thereof) to induce a response in PBMC or lymph node cell cultures may be evaluated by contacting the cells with the polypeptide and measuring a suitable response. In general, the amount of polypeptide that is sufficient for the evaluation of about 2 x 10 5 cells ranges from about 10 ng to about 100 μg, and preferably is about 1-10 μg. The incubation of polypeptide with cells is typically performed at 37°C for about 1-3 days. Following incubation with polypeptide, the cells are assayed for an appropriate response. If the response is a proliferative response, any of a variety of techniques well known to those of ordinary skill in the art may be employed. For example, the cells may be exposed to a pulse of radioactive thymidine and measuring the incoφoration of label into cellular DNA. In general, a polypeptide that results in at least a three fold increase in proliferation above background (i.e., the proliferation observed for cells cultured without polypeptide) is considered to be able to induce proliferation. Altematively, the response to be measured may be the secretion of one or more cytokines (such as interferon-γ (IFN-γ), interleukin-4 (IL-4), interleukin- 12 (p70 and/or p40), interleukin-2 (IL-2) and/or tumor necrosis factor-α (TNF-α)) or the level of mRNA encoding one or more specific cytokines. In particular, the secretion of interferon-γ, interleukin-2, tumor necrosis factor-α and/or interleukin- 12 is indicative of a Thi response, which is responsible for the protective effect against Leishmania. Assays for any of the above cytokines may generally be performed using methods known to those of ordinary skill in the art, such as an enzyme-linked immunosorbent assay (ELISA). Suitable antibodies for use in such assays may be obtained from a variety of sources such as Chemicon. Temucula, CA and PharMingen, San Diego, CA, and may generally be used according to the manufacturer ' s instructions. The level of mRNA encoding one or more specific cytokines may be evaluated by, for example, amplification by polymerase chain reaction (PCR). In general, a polypeptide that is able to induce, in a preparation of about 1-3 x 10" cells. the production of 30 pg/mL of IL-12, IL-4, IFN-γ, TNF-α or IL-12 p40, or 10 pg/mL of IL-12 p70, is considered able to stimulate production of a cytokine. Immunogenic portions of the antigens described herein may be prepared and identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed.. 243-247 (Raven Press. 1993) and references cited therein. Such techniques include screening polypeptides derived from the native antigen for immunogenic properties using, for example, the representative techniques described herein. An immunogenic portion of a polypeptide is a portion that, within such representative assays, generates an immune response (e.g., proliferation and/or cytokine production) that is substantially similar to that generated by the full length antigen. In other words, an immunogenic portion of an antigen may generate at least about 25%. and preferably at least about 50%, of the response generated by the full length antigen in the model assays described herein. Portions and other variants of immunogenic Leishmania antigens may be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 55:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Applied BioSystems, Inc., Foster City, CA, and may be operated according to the manufacturer's instructions. Recombinant polypeptides containing portions and/or variants of a native antigen may be readily prepared from a DNA sequence encoding the antigen. For example, supematants from suitable host/vector systems which secrete recombinant protein into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant protein. In general, any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes. yeast and higher eukaryotic cells. Preferably, the host cells employed are E coli, yeast or a mammalian cell line such as COS or CHO. The DNA sequences expressed in this manner may encode naturally occurring antigens, portions of naturally occurring antigens, or other variants thereof. For example, variants of a native antigen may generally be prepared using standard mutagenesis techniques, such as oligonucleotide- directed site-specific mutagenesis, and sections of the DNA sequence may be removed to permit preparation of truncated polypeptides. In certain aspects of the present invention, described in detail below, the polypeptides and/or soluble Leishmania antigens may be incoφorated into pharmaceutical compositions or vaccines. Pharmaceutical compositions comprise one or more polypeptides. each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier. Vaccines comprise one or more of the above polypeptides and a non-specific immune response enhancer, such as an adjuvant (e.g., LbeIF4A, interleukin- 12 or other cytokines) or a liposome (into which the polypeptide is incoφorated). Vaccines may additionally contain a deliver}' vehicle, such as a biodegradable microsphere (disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109). Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other Leishmania antigens, either incoφorated into a combination polypeptide or present within one or more separate polypeptides. Altematively, a vaccine may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. In such vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox vims, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Techniques for incoφorating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked." as described. for example, in Ulmer et al.. Science 259:1745-1749 (1993) and reviewed by Cohen, Science 259: 1691-1692 (1993). The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol. a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109. Any of a variety of adjuvants may be employed in the vaccines of this invention to nonspecifically enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism. such as aluminum hydroxide or mineral oil. and a nonspecific stimulator of immune responses, such as lipid A, Bordello pertussis or Mycobacterium tuberculosis. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit. MI), Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ), alum, biodegradable microspheres, monophosphoryl lipid A and quil A. Preferred adjuvants include LbeIF4A, IL-12 and other cytokines such as IFN-γ or granulocyte-macrophage colony stimulating factor (GM-CSF). By virtue of its ability to induce an exclusive Thi immune response, the use of LbeIF4A, and variants thereof, as an adjuvant in the vaccines ofthe present invention is particularly preferred. In one preferred embodiment, compositions of the present invention include multiple polypeptides selected so as to provide enhanced protection against a variety of Leishmania species. Such polypeptides may be selected based on the species of origin of the native antigen or based on a high degree of conservation of amino acid sequence among different species of Leishmania. A combination of individual polypeptides may be particularly effective as a prophylactic and/or therapeutic vaccine because (1 ) stimulation of proliferation and/or cytokine production by individual polypeptides may be additive, (2) stimulation of proliferation and/or cytokine production by individual polypeptides may be synergistic, (3) individual polypeptides may stimulate cytokine profiles in such a way as to be complementary to each other and/or (4) individual polypeptides may be complementary to one another when certain of them are expressed more abundantly on the individual species or strain of Leishmania responsible for infection. A preferred combination contains polypeptides that comprise immunogenic portions of Ml 5, Ldp23, Lbhsp83, Lt-1 and LbeIF4A. Alternatively, or in addition, the combination may comprise soluble Leishmania antigens. The above pharmaceutical compositions and vaccines may be used, for example, to induce protective immunity against Leishmania in a patient, such as a human or a dog, to prevent leishmaniasis. Appropriate doses and methods of administration for this puφoses are described in detail below. The pharmaceutical compositions and vaccines described herein may also be used to stimulate an immune response, which may be cellular and/or humoral, in a patient. For Leishmania-infected patients, the immune responses that may be generated include a preferential Thi immune response (i.e., a response characterized by the production of the cytokines interleukin- 1, interleukin-2, interleukin- 12 and/or interferon-γ, as well as tumor necrosis factor-α). For uninfected patients, the immune response may be the production of interleukin- 12 and/or interleukin-2, or the stimulation of gamma delta T-cells. In either category of patient. the response stimulated may include IL-12 production. Such responses may also be elicited in biological samples of PBMC or components thereof derived from Leishmania-infected or uninfected individuals. As noted above, assays for any of the above cytokines may generally be performed using methods known to those of ordinary skill in the art, such as an enzyme-linked immunosorbent assay (ELISA). Suitable pharmaceutical compositions and vaccines for use in this aspect of the present invention are those that contain at least one polypeptide comprising an immunogenic portion of LbeIF4A (or a variant thereof), Ml 5, soluble Leishmania antigens and or Ldp23 (or a variant thereof). Polypeptides comprising an immunogenic portion of Lbhsp83 and/or Lt-1 may also be used, in combination with a polypeptide that contains at least an immunogenic portion of LbeIF4A. Preferably, the polypeptides employed in the pharmaceutical compositions and vaccines are complementary, as described above. A particularly preferred combination contains polypeptides that comprise immunogenic portions of M15, Ldp23, Lbhsp83, Lt-1 and LbeIF4A. Soluble Leishmania antigens, with or without additional polypeptides, may also be employed. The pharmaceutical compositions and vaccines described herein may also be used to treat a patient afflicted with a disease responsive to IL-12 stimulation. The patient may be any warm-blooded animal, such as a human or a dog. Such diseases include infections (which may be, for example, bacterial, viral or protozoan) or diseases such as cancer. In one embodiment, the disease is leishmaniasis, and the patient may display clinical symptoms or may be asymptomatic. In general, the responsiveness of a particular disease to IL-12 stimulation may be determined by evaluating the effect of treatment with a pharmaceutical composition or vaccine of the present invention on clinical correlates of immunity. For example, if treatment results in a heightened Thi response or the conversion of a Th2 to a Thi profile, with accompanying clinical improvement in the treated patient, the disease is responsive to IL-12 stimulation. Polypeptide administration may be as described below, or may extend for a longer period of time, depending on the indication. Preferably, the polypeptides employed in the pharmaceutical compositions and vaccines are complementary, as described above. A particularly preferred combination contains polypeptides that comprise immunogenic portions of Ml 5. Ldp23, Lbhsp83, Lt-1 and LbeIF4A. Soluble Leishmania antigens, with or without additional polypeptides. may also be employed. Routes and frequency of administration, as well as dosage, for the above aspects ofthe present invention will vary from individual to individual and may parallel those currently being used in immunization against other infections, including protozoan, viral and bacterial infections. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 12 doses may be administered over a 1 year period. For therapeutic vaccination (i.e., treatment of an infected individual), 12 doses are preferably administered, at one month intervals. For prophylactic use, 3 doses are preferably administered, at 3 month intervals. In either case, booster vaccinations may be given periodically thereafter. Altemate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that, when administered as described above, is capable of raising an immune response in an immunized patient sufficient to protect the patient from leishmaniasis for at least 1-2 years. In general, the amount of polypeptide present in a dose (or produced in situ by the DNA in a dose) ranges from about 100 ng to about lmg per kg of host, typically from about 10 μg to about 100 μg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL. In another aspect, this invention provides methods for using one or more of the polypeptides described above to diagnose Leishmania infection in a patient using a skin test. As used herein, a "skin test" is any assay performed directly on a patient in which a delayed-type hypersensitivity (DTH) reaction (such as induration and accompanying redness) is measured following intradermal injection of one or more polypeptides as described above. Such injection may be achieved using any suitable device sufficient to contact the polypeptide or polypeptides with dermal cells of the patient, such as a tuberculin syringe or 1 mL syringe. Preferably, the reaction is measured at least 48 hours after injection, more preferably 72 hours after injection. The DTH reaction is a cell-mediated immune response, which is greater in patients that have been exposed previously to a test antigen (i.e., an immunogenic portion of a polypeptide employed, or a variant thereof). The response may measured visually, using a mler. In general, induration that is greater than about 0.5 cm in diameter, preferably greater than about 1.0 cm in diameter, is a positive response, indicative of Leishmania infection, which may or may not be manifested as an active disease. The polypeptides of this invention are preferably formulated, for use in a skin test, as pharmaceutical compositions containing at least one polypeptide and a physiologically acceptable carrier, as described above. Such compositions typically contain one or more of the above polypeptides in an amount ranging from about 1 μg to 100 μg, preferably from about 10 μg to 50 μg in a volume of 0.1 mL. Preferably, the carrier employed in such pharmaceutical compositions is a saline solution with appropriate preservatives, such as phenol and/or Tween 80™. The following Examples are offered by way of illustration and not by way of limitation. EXAMPLES Example 1 Preparation of M 15 This Example illustrates the preparation of a Leishmania antigen Ml 5, having the sequence provided in SEQ ID NO:2. An L. major (Friedlan strain) amastigote cDNA expression library prepared in the λZAP II vector (Stratagene, La Jolla, CA) was screened according to manufacturer's instmctions using sera obtained from L. major infected BALB/c mice (8 weeks post inoculation). Approximately 40,000 plaques were screened and four clones expressing reactive antigens were purified to homogeneity by two subsequent rounds of low density screening. Bluescript phagemid inserts were excised from positive clones for further analysis. An EcoRI/Sstll restriction fragment from the 5' end of one partial cDNA insert isolated during first round screening (pLmal-1) was subsequently used as a probe to rescreen for clones containing full length cDNA inserts. The probe was labeled to high specific activity (~10 9 cpm/μg) with fα- 32 P]dCTP using the random primer method and was used to screen ~ 10,000 plaques of the L major expression library described above. Positive clones were compared by restriction enzyme digestion and the clone with the largest insert (pfll-1 ) was chosen for subsequent analysis. DNA sequence analyses were performed on an Applied Biosystems automated sequencer using Taq polymerase and dye coupled ddNTP terminators or dye-labeled sequencing primers. The complete sequence of the 2685 bp insert was determined using a combination of primer-directed sequencing and by sequencing a series of overlapping Exonuclease III deletion subclones generated using the Erase-a- base system (Promega, Madison, WI). The sequence of this insert is provided in SEQ ID NO:l , and the deduced amino acid sequence is provided in SEQ ID NO:2. The complete insert of clone pfl-1 was excised by digestion with BamHl/Kpnl and was subcloned in frame into BamHl/Kpnl digested pQE31 (QUIAGEN) to generate the constmct pM151A. E. coli containing this constmct inducibly expressed high levels of the L. major antigen encoded by pfll-1 (designated as Ml 5) with the addition of a 6-histidine tag at the amino terminus. Large volume cultures (500 ml) of E. coli host cells containing the pM151A constmct were induced to express recombinant protein by the addition of 2mM IPTG at mid-log phase of growth. Growth was continued for 4 to 5 hours and bacteria were then pelleted and washed once with cold PBS. Bacteria were resuspended in 20 ml of lysis buffer (50 mM Na 2 HPO 4 , pH 8.0, 300 mM NaCl, 10 mM /3-mercaptoethanol) containing 20 mg of lysozyme and were lysed by a 1 hour incubation at 4°C followed by brief sonication. Insoluble material was removed by centrifugation at 10,000xg for 10 minutes and although the recombinant protein was found to be evenly distributed between the soluble and insoluble fractions the insoluble material was discarded at this point. Recombinant protein containing the amino terminal histidine tag was affinity purified using Ni-NTA resin (QIAGEN) according to the manufacturer's recommendations. Briefly, 8 ml of Ni-NTA resin resuspended in lysis buffer was added to the soluble lysate fraction and binding was conducted with constant mixing for 1 hour at 4°C. The mixture was then loaded into a gravity flow column and the non-binding material was allowed to flow through. The Ni-NTA matrix was washed 3 times with 25 ml of wash buffer (50 mM Na : HPO 4 , pH 6.0, 300 mM NaCl, 10 mM /?-mercaptoethanol) and bound material was eluted in 25 ml of elution buffer (50 mM Na 3 HPO 4 , pH 5.0, 300 mM NaCl, lOmM β- mercaptoethanol). The eluted material was then dialyzed against 3 changes of PBS, sterile filtered and stored at -20°C. The purified recombinant protein was shown by SDS-PAGE analysis to be free of any significant amount of E. coli protein. A small number of bands of lower molecular weight were assumed to be proteolytic products of the L. major antigen based on their reactivity by western blot analysis. A high titre polyclonal antisera against Ml 5 was generated in rabbits by repeated subcutaneous injection of recombinant protein. Western blot analysis of lysates from L. major promastigotes and amastigotes using this antisera indicated that the protein is constitutively expressed throughout the parasite lifecycle. Example 2 Preparation of Ldp23 This Example illustrates the preparation of a Leishmania antigen Ldp23, having the sequence provided in SEQ ID NO:4. A. Purification of MHC Class H-associated Peptides from P388D1 Macrophages Infected with L. donovani To ascertain that in vitro infection of macrophages would load their MHC class II molecules with parasite peptides, initial experiments were carried out to test the ability of L. donovani-infected macrophage cell line P388D1 to present parasite antigens to L. donovani specific T-cells. This macrophage cell line was chosen because it has the same H-2 haplotype as the BALB/c mouse, which is a strain of mouse moderately susceptible to L. donovani infection and selected to conduct the in vivo experiments. Using a proportion of 3-5 parasites per cell and an initial incubation at room temperature for 4-6 hours follows by 37°C for 24-48 hours, close to 90% of the macrophages were infected. The level of MHC class II molecule expression, as determined by FACS analysis, indicated that infection did not cause an effect on the levels of MHC class II expression when compared to non-infected control cells. To test the ability of the L. donovani-infected P388D1 cells to present parasite antigens, macrophages were infected as indicated above and incubated at 26°C for 6 hours, and then as 37°C for either 24, 48 or 72 hours. At each of these time points the non-adherent cells and free parasites were washed out and the adherent cells were mechanically dislodged, washed and fixed with paraformaldehyde. These cells were then used as antigen presenting cells (APCs) for purified lymph node T-cells from BALB/c mice immunized with L. donovani promastigotes. To generate these anti-E donovani specific T-cells, BALB/c mice (H-2 d ) of both sexes (The Jackson Laboratory, Bar Harbor, ME) were immunized at 8 to 14 weeks of age in the rear foot pad with 5-10 x IO 6 L. donovani promastigotes emulsified in complete Freund's adjuvant (CFA) (Difco Laboratories, Madison, MI) as described in Rodrigues et al.. Parasite Immunol. 14:49 (1992). The draining lymph nodes were excised 8 days after the immunization and T-cells were purified in an anti-mouse Ig column to remove the B cells. as described in Bunn-Moreno and Campos-Neto, J. Immunol. 127:427 (1981), followed by a passage through a Sephadex G10 column to remove the macrophages. Stimulation index was calculated by dividing the cpm obtained for the cells cultured in the presence of infected P388D1 macrophages by the cpm obtained for the cells cultured in the presence of non-infected macrophages, but subjected to the same conditions as the infected macrophages. The results shown Figure 1 indicate that L donovani-infected P388D1 macrophage process parasite antigens and that optimal presentation occurs after 48 hours of infection. No stimulation of the T-cells by the non- infected macrophages was observed. To isolate the MHC class II associated L. donovani peptides, P388D1 macrophages were infected with L. donovani promastigotes for an initial incubation of 6 hours at room temperature. The cultures were then transferred to 37°C for the remainder of the 48 hour incubation period. At a ratio of 3-5 parasites per macrophage nearly 90% of the macrophages were infected after 24 hours of incubation at 37°C. The MHC class II molecules were then affinity-purified. Approximately 1.5 x 10 10 L. donovani-infected or an equal number of non-infected P388D1 macrophages were used for each purification. The cells were harvested, washed with PBS and incubated for 30 minutes in cold lysis buffer (PBS, 1% Nonidet P40, 25mM iodoacetamide, 0.04% sodium azide. lmM aprotinin and lmM PMSF). The insoluble material was removed by centrifugation at 40,000g for 1 hour and the supematant was recycled ovemight at 4°C over a 5ml anti-MHC class II molecules (H-2 d ) Sepharose column (Protein G Sepharose column to which the monoclonal antibody MK-D6 has been bound). Culture supematants of MK-D6 hybridoma cells (American Type Culture Collection, Rockville, MD) were employed as the source for anti-MHC class II (H-2 d ) monoclonal antibody. The column was washed with 50ml of lysis buffer and then with 50ml of PBS containing 0.5% octyl glucopyranoside detergent. Bound molecules were eluted from the column with IM acetic acid in 0.2% NaCl. The MHC/peptide molecules were separated from the IgG (MK-D6 monoclonal antibody) using a Centricon 100 filter unit (Amicon Division, W.R. Grace & Co., Beverly, MA). The peptides were then dissociated from the class II molecules by the addition of acetic acid to 2.5M, followed by separation using a Centricon 10 filter unit. The resulting peptide preparation, present in the low molecular weight sample, was then dried using a speed vac concentrator (Savant Instmment Inc., Farmingdale, NY). The peptides were redissolved in 200μl of 0.05% TFA and separated by reverse-phase high performance liquid chromatography (RP-HPLC) using a 2.1mm x 25cm Vydac C-18 column at a flow rate of 0.15ml/min employing a 1 to 30% acetonitrile gradient (60 min) followed by a 30 to 60% gradient (30 min) and then a 60 to 80% gradient (90-1 10 min). Non-infected P388D1 cells were similarly processed to serve as background control for endogenous MHC class II associated peptides. Figure 2 shows a representative experiment; four distinct peaks which are present only in the material isolated from infected macrophages (panel B), and not in the material isolated from uninfected macrophages (panel A) are indicated. Out of three independent peptide extractions, twenty five distinct HPLC peptide peaks were isolated from L. donovani-infected macrophages and were subjected to protein sequence analysis using automated Edman degradation on an Applied Biosystems 477 gas-phase protein sequencer. Protein sequence and amino acid analysis were performed by the W.M. Keck Foundation, Biotechnology Resource Laboratory, Yale University, New Haven, CT. In practically all determinations, no assignment could be made for the first position. Also, in most cases the definition of the amino acid residues of the 10-15 positions was based on the quantitative dominance of one residue over others. Using this approach, the sequences obtained for several peptides showed the presence of 3-6 different residues in many of the 10-15 sequence cycles analyzed for each determination, reflecting a mixture of peptides. In addition, sequences could not be obtained for some peaks because the peptides were blocked. Notwithstanding, three peptides sequences were determined. Amino-acid sequences were searched for identity with proteins in the GenBank database using the GENPETP, PIR and SWISSPROT programs. The sequence data base analysis revealed that one of the peptides was highly homologous to glyceraldehyde-3 -phosphate dehydrogenase of various species. Another peptide had homology with elongation factor of several species, including Leishmania. The third sequence was not clearly related to any known proteins, and is shown below: XQXPQ(L/K)VFDEXX. B. Cloning and Sequencing ofthe Ldp23 Gene In order to retrieve the L donovani protein that was processed into a peptide associated with the MHC class II molecules of infected macrophages, the peptide sequence of uncertain origin was chosen to guide the strategy for cloning the corresponding parasite gene. A DNA fragment was initially amplified from L donovani promastigote cDNA by PCR. The sense primer was a peptide derived oligonucleotide (5' > GGAATTCCCCInCAGCTInGTInTTCGAC < 3') containing an EcoRI restriction endonudease site (underlined). The bases were selected following the preferential codon usage of I. donovani, as described in Langford et al., Exp. Parasitol. 7-^:360 (1992). Inosine was used for the residues of positions 4, 6 and 7 because of the low codon usage assurance for the corresponding amino acids. In addition, the carboxyl-terminal L-glutamic acid was not included for the design of the primer. The antisense primer was a poly-thymidine oligonucleotide (oligo dT, downstream primer) containing a Xhol restriction endonudease site. The gene fragment was amplified from a L. donovani promastigote cDNA preparation using the following reaction conditions: one cycle of 3 min at 94°C immediately followed by 35 cycles of 1 min at 94°C, 1 min at 45°C and 1 min at 72°C. The L. donovani cDNA was prepared from 5 x 10 7 washed promastigote forms harvested at the log growth phase (3 days culture). The cDNA was obtained using an Invitrogen cDNA cycle™ kit (Invitrogen Co., San Diego, CA). Oligonucleotide primers were synthesized by the DNA Synthesis Laboratory, Department of Pathology, Yale University School of Medicine. The PCR products were analyzed by gel electrophoresis. Only one band of approximately 300 bp was obtained. This fragment was cloned and its sequence confirmed the sequence of the peptide-based primer including the glutamic acid codon, deliberately not included in the primer sequence. The PCR amplified gene fragment was ligated into the pCR™ vector using the TA cloning system (Invitrogen Co., San Diego, CA). Transformants were selected in LB medium containing lOOμg/ml ampicillin and the plasmid DNA was isolated using the Wizard™ Minipreps DNA purification kit (Promega Co., Madison, WI). Insert DNA was released with the restriction enzymes EcoRI and Xhol (New England Biolabs, Beverly, MA), purified from an agarose gel electrophoresis and labeled with 32 P using a random priming method (Megaprime Labeling Kit, Amersham Life Science, Buckinghamshire, England). This DNA fragment was used as probe to screen a L. donovani promastigote cDNA library as described in Skeiky et al.. Infect. Immun. 62:1643 (1994). An approximately 650 bp cDNA (Ldp23) was excised from the phagemid by in vivo excision using the Stratagene protocol. DNA sequencing was performed using the Sequenase version 2 system (DNA sequencing kit) in the presence or absence of 7- deaza-GTP (United States Biochemical, Cleveland, OH). The sequence is provided as SEQ ID NO:3. and shows complete homology with the original 300 bp PCR fragment. A 525 bp open reading frame containing an ATG codon that follows the last 4 bases of the spliced leader sequence and 3 stop codons adjacent to the poly A tail was identified. This frame also codes the carboxyl terminal sequence (KVFDE) of the purified MHC class II associated peptide. The sequence analysis of the deduced protein sequence revealed one potential glycosylation site (Asn-Cys-Ser) at positions 68-70. Sequence analysis was performed using the University of Wisconsin Genetics Computer Group Programs and the GenBank and EMBL data bases of protein and DNA sequences. The search for homology of the Ldp23 gene with known sequences revealed no significant homology. _ Bacterial Expression and Purification of Recombinant Protein The recombinant L. donovani peptide donor protein was produced in E. coli transformed with the pGEX 2T expression vector in which the Ldp23 gene was subcloned in frame. PCR was used to subclone the cloned gene in frame into the expression vector pGEX 2T. Primers containing the appropriate restriction site enzymes, initiation and termination codons were: 5' > GGATCCATGGTCAAGTCCCA CTACATCTGC <3' for the upstream primer and 5' > GAATTCAGACCGGATAGAAA TAAGCCAATGAAA <3' for the downstream primer (restriction sites of BamHl and EcoRI are underlined respectively). PCR conditions were as indicated above for the amplification of the original peptide related DNA fragment. The template used was pBluescript plasmid containing the cloned gene from the cDNA library. Overexpression of the recombinant fusion protein was accomplished by growing the transformed E. coli (DH5α) and inducing the tac promoter with lmM isopropyl-β-thiogalactopyranoside (IPTG) (Stratagene. La Jolla, CA). Cells were collected, centrifuged, and analyzed for the presence of the fusion protein by SDS- PAGΕ. A glutathione-S-transferase fusion protein of 43-44 kD was produced. indicating a leishmanial protein of approximately 18 kD, as glutathione-S-transferase (GST) has a MW of 26 kD. However, the fusion protein was very insoluble and therefore could not be purified by affinity chromatography using a glutathione column. The use of low concentrations of detergents like SDS, sarcosyl, deoxycolate, and octyl- glucopyranoside during the extraction steps was efficient to solubilize the protein but unfortunately prevented its binding to the glutathione column. Other maneuvers, such as the growth of the E. coli and incubation and induction of the tac promoter with IPTG at 33 °C, did not improve the protein solubility. However, the purification was achieved by preparative SDS-PAGΕ. The band was visualized with 0.1M KCl, cut and electroeluted from the gel followed by extensive dialysis against PBS and concentration on Centricon 10 filters. Approximately 500μg of purified protein was obtained. The purified protein is shown in Figure 3. In panel A, E. coli (DH5α) transformed with the expression vector pGΕX 2T containing the Ldp23 gene was grown in LB medium and the tac promoter was induced with IPTG for 3 hours. The cells were pelleted, resuspended in loading buffer and submitted to SDS-PAGΕ (10%) under reducing condition. The gel was stained with Coomassie blue. Lane 1 shows the uninduced E. coli and land 2 shows the induced E. coli. The arrow indicates the recombinant protein. Panel B shows the protein prepared as in panel A and submitted to a preparative SDS- PAGE. The band corresponding to the overexpressed recombinant fusion protein was identified by KCl. cut out. electroeluted from the gel strip, dialyzed against PBS and submitted to analytical SDS-PAGE (12%). Numbers on the left side indicate the molecular weights ofthe markers. Attempts to further purify the leishmanial protein by- cleaving it out from the fusion protein GST with thrombin were unsuccessful. D. Expression of Ldp23 To ascertain that the Ldp23 peptide is expressed in Leishmania organisms, a Northern blot analysis was performed using RNA prepared from different promastigote growth phases (logarithmic and stationary) and from the amastigote form of these parasites. The RNA was prepared from 2 x 10 7 parasite cells using the Micro R A isolation kit (Stratagene. La Jolla. CA) according to the company's recommended instructions. RNA was prepared from L. donovani promastigotes (logarithmic growth phase); from L. major promastigotes (logarithmic and stationary growth phases); from L amazonensis. both promastigotes (logarithmic and stationary growth phases) and amastigotes purified from CBA/J infected mice; and from L pifanoi, both promastigotes (logarithmic and stationary growth phases) and amastigotes (from axenic culture medium). L. donovani (I S strain), L amazonensis (MHOM/BR 77/LTB0016), L. major (MHOM/IR 79/LRC-L251) and L. pifanoi (MHOM/VE/60/Ltrod) promastigotes were grown and maintained at 26°C in Schneider's medium containing 20% FCS and 50μg/ml gentamicin. The amastigote forms of L amazonensis were obtained by differential centrifugation of a "pus-like" foot pad lesion of a CBA J mouse infected for 6 months with this parasite. L. pifanoi amastigotes were obtained from axenic culture as previously reported by Pan et al., J. Euk. Microbiol. 40:2 3 (1993). The hybridization was carried out at 45°C in the presence of 50% formamide, 5x Denhardt's solution. 0.1 % SDS, lOOμg/ml single stranded salmon sperm DNA and 5x SSPE using 0.45μm Nytran membrane filters (Schleicher & Schuell, Keene, NH). The probe was the 32 P labeled Ldp23 gene. Figure 4 shows that one single RNA band of 680 bp was observed for all growth phases and forms of all tested Leishmania. Within Figure 4, the numbers 1. 2 and 3 refer to RNA obtained from promastigotes at the logarithmic growth phase, promastigotes at the stationary growth phase and amastigote forms, respectively, and the numbers on the left side indicate the molecular weights ofthe markers in base pairs. This result is consistent with the corresponding gene size (525 bp) and with the molecular weight of the expressed protein and points to the ubiquitous distribution and expression of this gene within the genus Leishmania. E. Induction of Anti-Z,. donovani Antibody Response in Mice and Rabbits bv Purified Recombinant Protein In order to evaluate the immunogenicity of the recombinant leishmanial protein, and to investigate its expression in the parasites, mice and rabbits were immunized with the GST-fusion protein in CFA. BALB/c mice were immunized in the rear foot pad with 5-10μg of protein emulsified in CFA. Protein concentration was determined using the Bio-Rad Protein Assay reagent (Bio-Rad Laboratories, Richmond, CA). The mice were boosted 7 days later with 5-1 Oμg of protein emulsified in incomplete Freund's adjuvant (IFA) inoculated into the peritoneal cavity. The mice were bled 7 days after the second immunization. New Zealand white rabbits (Millbrook Farm. Amherst. MA) were immunized according to the following protocol: one intra-muscular (IM) injection of 25-30μg of purified recombinant protein emulsified in CFA into each thigh on day one; one IM injection of 25-30μg of purified protein emulsified in IFA into each shoulder on day 7; on day 15, 25-30μg of the purified protein in PBS was injected into the subcutaneous tissue. The rabbit was bled 7 days after the last immunization. Sera were prepared and the a ti-Leishmania antibody response was measured by Western blot analysis and by FACScan. In both cases L. donovani promastigotes were used as antigen. Approximately 2 x IO 6 L. donovani promastigotes were grown in Schneider's medium for 3 days (log phase), were washed with PBS, lysed with SDS-PAGE loading buffer and submitted to electrophoresis under reducing conditions using a 15% polyacrylamide gel. The proteins were transferred onto 0.45 μ Immobilon-P transfer membrane (Millipore Co.. Bedford, MA) using a wet-type electroblotter (Mini Trans-Blot Electrophoretic Transfer Cell, Bio Rad Life Science Division, Richmond, CA) for 2 hours at 50 V. The membranes were blocked ovemight at room temperature with PBS containing 3% normal goat serum (NGS), 0.2% Tween- 20 and 0.05% sodium azide. followed by 3 washes with PBS. The blots were then incubated for 3-4 hours at 4°C with a 1/200 dilution of pre-immune rabbit semm (lane A, Figure 5) or with the same dilution of anti-fusion protein rabbit antisemm (lane B, Figure 5). The sera was previously absorbed 2x with non-viable desiccated Mycobacterium tuberculosis H-37 RA (Difco Laboratories. Detroit. MI) and were diluted in PBS containing 1 % NGS and 5% powdered non-fat bovine milk (Carnation, Nestle Food Company, Glendale, CA). The membranes were then washed with PBS, incubated for 1 hour at room temperature with goat anti-rabbit IgG antibody conjugated with alkaline phosphatase (Promega, Madison, WI). washed once with PBS and 2x with veronal buffer pH 9.4. The reaction was visualized using the substrate mixture 5- bromo-4-chloro-3-indoyl-phosphate and nitroblue tetrazolium (Kirkegaard & Perry Laboratories Inc., Gaithersburg. MD) according to the manufacturer's instmctions. Figure 5 shows that the rabbit anti-recombinant protein antiserum detects a single protein of 23 kDa (Ldp23) in the Leishmania cmde extract antigen preparation. No bands were observed when an anti-GST antisemm was used (not shown). Moreover, the FACScan analysis (Figure 6) shows that the antibody induced by the recombinant Ldp23 reacts with intact live L. donovani promastigotes, thus pointing to a cell surface expression of this molecule on these organisms. The dotted line in Figure 6 shows the indirect immunofiuorescence performed using pre-immune mouse semm and the solid line in Figure 6 shows the result obtained with mouse anti- GST-Ldp23 antisemm. Both sera were diluted at 1/100. Parasites were washed with staining buffer and incubated with FITC conjugated goat anti-mouse immunoglobulin antibody. Fluorescence intensity was analyzed by FACScan. F. Recognition of Recombinant Ldp23 bv Leishmania-Specific Lymph Node T- cells To test the responsiveness of T-cells to the Ldp23 protein, two sets of experiments were performed. In the first experiment, lymph node T-cells (lOVwell) from BALB/c mice immunized with L. donovani promastigotes (as described above) were stimulated to proliferate with 2 x 10 5 Mitomycin C-treated normal mononuclear spleen cells (APC) and pulsed with the purified recombinant fusion protein. Proliferation of T-cells was measured at 72 hours of culture. Values are expressed in Figure 7 as cpm and represent the mean of [ 3 H]TdR incoφoration of triplicate cultures. Background cpm of cells (T cells + APC) cultured in the presence of medium alone was 1291. Figure 7 shows that Leishmania specific T-cells proliferate well and in a dose response manner to recombinant Ldp23. No response was observed when purified GST was added instead of the recombinant fusion protein nor when lymph node T-cells from mice immunized with CFA alone were stimulated to proliferate in the presence of the Leishmanial fusion protein (not shown). The recognition of the recombinant Ldp23 protein by Leishmania- specific T-cells was also tested using two murine models of leishmaniasis, the L. major highly susceptible BALB/c mice and the L. amazonensis susceptible CBA/J mice as described in Champsi and McMahon-Pratt, Infect. Immun. 56:3272 (1988). These models were selected to investigate the cytokine pattem induced by Ldp23. In the mouse model of leishmaniasis, resistance is associated with Th 1 cytokines while susceptibility is linked to Th 2 responses. Lymph node cells were obtained 3 weeks after the initiation of infection of BALB/c mice with L. major and the ability of these cells to recognize the recombinant Ldp23 was measured by proliferation and by the production of the cytokines IFN-γ and IL-4. 2 x IO 6 cells obtained from the draining popliteal lymph node of infected mice were cultured for 72 hours in the presence of recombinant Ldp23 or Leishmania lysate. The levels of IFN-γ and IL-4 in culture supematants were measured by ELISA as previously described (Chatelain et al.. J. Immunol. 148: 172 (1992), Curry et al.. J. Immunol Meth. 104:137 (1987), and Mossman and Fong, J. Immunol. Meth. 776:151 (1989)) using specific anti IFN-γ and IL-4 monoclonal antibodies (PharMingen. San Diego. CA). Ldp23 did stimulate these cells to proliferate (not shown) and induced a typical Th 1 type of cytokine response as indicated by the production of high levels of IFN-γ (panel A of Figure 8) and no IL-4 (panel B of Figure 8). Stimulation of these cells with a Leishmania crude lysate yielded a mixed Th cytokine profile. Exactly the same pattem of cytokine production was obtained from the CBA/J mice infected with L. amazonensis (not shown). These results clearly indicate that Ldp23 is a powerful and selective activator of the Th 1 cytokines by mouse cells. Example 3 Preparation of Hsp83 This Example illustrates the preparation of a Leishmania antigen Hsp83. having the sequence provided in SEQ ID NO:6. A genomic expression library was constmcted with sheared DNA from L. braziliensis (MHOM/BR/75/M2903) in bacteriophage λZAP II (Stratagene. La Jolla, CA). The expression library was screened with Escherichia coli preadsorbed serum from an L braziliensis-infected individual with ML. Immunoreactive plaques were purified, and the pBSK(-) phagemid was excised by protocols suggested by the manufacturer. Nested deletions were performed with exonuclease III to generate overlapping deletions for single-stranded template preparations and sequencing. Single-stranded templates were isolated following infection with VCSM13 helper phage as recommended by the manufacturer (Stratagene, La Jolla, CA) and sequenced by the dideoxy chain terminator method or by the Taq dye terminator system using the Applied Biosystems automated sequencer model 373A. Recombinant antigens produced by these clones were purified from 500 ml of isopropyl-β-D-thiogalactopyranoside (IPTG)-induced cultures as described in Skeiky et al., J. Exp. Med. 776:201-21 1 (1992). These antigens were then assayed for the ability to stimulate PBMC from Leishmania-infected individuals to proliferate and secrete cytokine. Peripheral blood was obtained from individuals living in an area (Corte de Pedra, Bahia. Brazil) where L. braziliensis is endemic and where epidemiological, clinical, and immunological studies have been performed for over a decade, and PBMC were isolated from whole blood by density centrifugation through Ficoll (Winthrop Laboratories, New York, N.Y.). For in vitro proliferation assays, 2 X 10' to 4 X 10 5 cells per well were cultured in complete medium (RPMI 1640 supplemented with gentamicin. 2-mercaptoethanol. L-glutamine. and 10% screened pooled A+ human semm; Trimar. Hollywood. Calif.) in 96-well flat-bottom plates with or without 10 μg of the indicated antigens per ml or 5 μg of phytohemagglutinin per ml (Sigma lmmunochemicals. St. Louis, Mo.) for 5 days. The cells were then pulsed with 1 μCi of [ 3 H]thymidine for the final 18 h of culture. For determination of cytokine production 0.5 to 1 ml of PBMC was cultured at 1 X IO 6 to 2 X IO 6 cells per ml with or without the Leishmania antigens for 48 and 72 h. The supematants and cells were harvested and analyzed for secreted cytokine or cytokine mRNAs. Aliquots of the supematants were assayed for gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin-4 (IL-4), and IL-10 as described in Skeiky et al., J. Exp. Med. 181: 1527- 537 (1995). For cytokine mRNA PCR analysis, total RNA was isolated from PBMC and cDNA was synthesized by using poly(dT) (Pharmacia, Piscataway, NJ) and avian myeloblastosis vims reverse transcriptase. Following normalization to β-actin, diluted cDNA was amplified by PCR using Taq polymerase (Perkin-Elmer Cetus, Foster City, CA) with 0.2 μM concentrations ofthe respective 5' and 3' extemal primers in a reaction volume of 50 μl. The nucleotide sequences of the primary pairs and the PCR conditions used were as described in Skeiky et al., J Exp. Med. 181:1527-1537 (1995). We verified that our PCR conditions were within the semiquantitative range by initially performing serial dilutions of the cDNAs and varying the number of cycles used for PCR. Plasmids containing the human sequences for IL-2, IFN-γ, IL-4, IL-10. and β-actin were digested, and the DNA inserts were purified after separation on 1% agarose gels. Radiolabeled 32 P probes were prepared by the random priming method. PCR products were analyzed by electrophoresis on 1.5% agarose gels, transferred to nylon membranes, and probed with the appropriate 32 P-labeled DNA insert. A recombinant clone was identified in the above assays which, following sequence comparison of its predicted amino acid sequence with sequences of other proteins, was identified as a Leishmania braziliensis homolog of the eukaryotic 83 kD heat shock protein (Lbhsp83). The sequence of the clone is provided in SEQ ID NO:5 and the deduced protein sequence is provided in SEQ ID NO:6. On the basis of the homology. this clone, designated Lbhsp83a, appears to lack the first 47 residues of the full length 703 amino acid residues. Lbhsp83 has an overall homology of 94% (91%) identity and 3% conservative substitution), 91% (84% identity and 7% conservative substitution) and 77% (61% identity and 16% conservative substitution) with L. amazonensis hsp83. T. cruzi hsp83 and human hsp89, respectively. A second clone (designated Lbhsp83b), which contained the 43 kD C-terminal portion of hsp83 (residues 331 to 703) was also isolated. Figure 19 presents a comparison of the Lbhsp83 sequence with L. amazonensis hsp83(Lahsp83), T. cruzi hsp83 (Tchsp83) and human hsp89 (Huhsp89). The results of proliferation assays using Lbhsp83a are shown in Table 1. Cells from all mucosal leishmaniasis (ML) patients proliferated strongly in response to Lbhsp83a, with stimulation indices (Sis) ranging from 19 to 558 (as compared to 20 to 1.634 for parasite lysate). Proliferation of PBMC from cutaneous leishmaniasis (CL) patients was variable and except for levels in two patients (IV and VII), levels were significantly lower than those of ML patients. By comparison, the proliferative responses of individuals with self-healing CL to Lbhsp83a were similar to those of individuals with ML. However, the responses of all six self-healing individuals to Lbhsp83 were consistently higher than those to Lbhsp83b. This suggests that PBMC from self-healing CL patients preferentially recognize one or more T-cell epitopes located within the amino portion of Lbhsp83. Table In vitro Proliferation of PMBC from L braziliensis-infected Individuals in Response to Lbhso83 Mean [ 3 H]thymidine incoφoration [10 3 cpm (SD)], SI with: Grouf i and Patient Lysate Lbhsp83a Lbhsp83b ML 1 41.3,(1.3), 294 32.5, (6.6), 221 46.7, (1.4), 318 II 44.2,(0.5).104 20. (3.7).47 36.7, (0.76), 86 II! 27.4,(1.5), 150 8.1.(1.7), 44 9.9, (0.32), 54 IV 52.7,(3.3).138 54.1,(6.2), 142 32.0, (1.3), 84 V 140.6, (7.6), 308 151.8, (57), 333 150.4, (7.9).331 VI 15.8, (1.8).20 21.3,(4.4).28 14.4,(1.3), 19 VII 300.1,(9.4), 1634 102.1,(7.6), 558 41.7, (4.9), 228 CL 1 0.26,(0.0), 1.5 0.57, (0.3), 3.3 0.43,(0.17), 3.3 II 55.63,(8.6), 218 0.42.(0.0), 1.6 0.8,(0.14), 3.2 III 0.39, (0.5), 4.0 3.4. (0.5).9 2.6, (0.9), 6.6 IV 19.14,(1.3), 87 7.17.(0.6), 32 5.9, (0.9), 27 V 0.32, (0.2), 3.0 1.47,(0.5).14 0.3,(0.1), 3.0 VI 0.77, (0.1).4.7 1.44. (0.2), 9 1.3,(0.6), 8.0 VII 4.01, (1.0).2.0 60.3.(8.5), 15 66.7,(3.9), 16.6 Self-healing CL I 19.7, (4.4), 94 61.3,(4.6).293 5.0, (2.0).24 I! 0.6, (0.1), 6.5 7.0. (2.0), 79 1.2,(0.8), 13 Ill 59.6, (7.1), 519 49.4, (3.1).429 21.4,(3.7), 186 IV 0.2,(0.1), 1.6 13.1,(1.7).108 0.6, (0.1), 5 V 27.1,(2.0), 225 6.3. (2.6), 52 3.0, (1.5), 25 VI 130.3,(14), 340 28.2, (2.9), 74 7.7, (3.8), 20 Control ( uninfected) I 0.19,(0.0), 1.4 0.18.(0.0), 1.3 0.40. (0.16), 2.8 II 0.31,(0.1).1.7 0.19,(0.0), 1.0 0.27,(0.0), 1.5 III 0.44, (0.2).4.1 0.48, (0.1), 5.0 0.51,(0.2), 5.2 IV 0.4, (0.1), 3.2 0.52, (0.2).5.1 0.50, (0.1), 5.0 A more detailed analysis of cytokine pattems of PBMC from ML patients was performed by reverse transcriptase PCR. Cytokine mRNAs were evaluated in cells prior to culturing (Figure 9, lanes O) or following culturing in the absence (lanes -) or presence of the indicated antigen for 48 and 72 h. Figure 4A shows the results for five ofthe six ML patients whose PBMC were analyzed. In about half of the ML patients, noncultured (resting) PBMC had detectable levels of mRNA for IFN-γ, IL-2, and IL-4 but not IL-10. CL patient PBMC, however, had IL-10 mRNA in the resting state in addition to mRNAs for the other cytokines tested (Figure 4B). Following in vitro culture without antigen, the levels of mRNA for IFN-γ, IL-2, and IL- 4 in resting cells from ML patients decreased to background levels while IL-10 mRNA levels increased. In contrast, PBMC of most CL patients had stable or increased IL-10 mRNA, while the mRNAs for IL-2, IFN-γ, and IL-4 were reduced to barely detectable levels in the absence of antigen stimulation. In PBMC of three ML patients, stimulation with lysate resulted in increased expression of mRNA for IFN-γ, IL-2, and IL-4 but not IL-10. By comparison, both Lbhsp83 polypeptides elicited the production of mRNA for IFN-γ and IL-2 from all ML patient PBMC tested. In contrast, profiles of mRNA for IL-10 and IL-4 differed for the two hsp83 polypeptides. Lbhsp83a stimulated the production of IL-10 but not IL-4 mRNA (patients I, II, III, and IV), while Lbhsp83b stimulated the production of IL-4 but not IL-10 mRNA in all six patients. All CL patients tested responded to both Lbhsp83 polypeptides as well as to the parasite lysate by upregulating the synthesis of mRNAs for IL-2 and IFN-γ, and in two of four patients (I and IV), the level of IL-4 mRNA also increased, indicating stimulation of both Thi and Th2 cytokines. Interestingly and as in the case of ML patient uncultured PBMC which did not have detectable levels of IL-10 mRNA, Lbhsp83a and not Lbhsp83b stimulated PBMC from one CL patient (IV) to synthesize IL-10 mRNA. However, in the other three patients (I, II, and III) with resting levels of IL-10 mRNA, both rLbhsp83 polypeptides as well as the parasite lysate downregulated the expression of IL-10 mRNA. PBMC supematants were also assayed for the presence of secreted IFN- γ. TNF-α, IL-4, and IL-10. Cells from all ML and self-healing CL patients (seven and six patients, respectively) and from four of seven CL patients were analyzed for secreted IFN-γ following stimulation with both rLbhsp83 polypeptides, parasite lysate and Lbhsp70. an L. braziliensis protein homologous to the eukaryotic 70 kD heat shock protein (Figure 10A). In general. rLbhsp83a stimulated patient PBMC to secrete higher levels of IFN-γ than did rLbhsp83b (0.2 to 36 and 0.13 to 28 ng/ml. respectively). The presence of secreted IFN-γ correlated well with the corresponding mRNA detected by PCR PBMC from four of five ML patients (I, II, V, and VII) had supematant TNF-α levels (0.8 to 2.2 ng/ml) higher than those detected in cultures of PBMC from uninfected controls following stimulation with parasite lysate (Figure 10B). Similarly, the same PBMC were stimulated by rLbhsp83 to produce levels of TNF-α in supematant ranging from 0.61 to 2.9 ng/ml. Compared with those of uninfected controls, PBMC from three (I, V, and VI), five (I, II, IV, V, and VI). and two (II and V) of six individuals analyzed produced higher levels of TNF-α in response to parasite lysate, rLbhsp83a, and rLbhsp83b. respectively. The levels of TNF-α produced by PBMC from CL patients in response to parasite lysate were comparable to those produced by uninfected controls. However, rLbhsp83 stimulated TNF-α production in the PBMC of two of these patients. rLbhsp83a stimulated higher levels of TNF-α production than did rLbhsp83b. In the absence of antigen stimulation, only PBMC from ML patients (five of six) produced detectable levels of supematant TNF-α (60 to 190 pg/ml). In agreement with the IL-10 mRNA, IL-10 was detected by ELISA in the antigen-stimulated PMBC culture supematants from ML and CL patients. The levels (49 to 190 pg) were significantly higher (up to 10-fold) following stimulation with rLbhsp83a compared with those after parallel stimulation of the same cells with rLbhsp83b (Figure 1 1). Parasite lysate also stimulated PMBC from some of the patients to produce IL-10. Although rLbhsp83 stimulated PMBC from uninfected individuals to produce IL-10, with one exception, the levels were lower than those observed with patient PMBC. IL-4 was not detected in any of the supematants analyzed. Therefore, the level of any secreted IL-4 is below the detection limit of the ELISA employed (50 pg/ml). Taken together, the results demonstrate that a predominant Thi -type cytokine profile is associated with PMBC from L. braziliensis- infected individuals following stimulation with rLbhsp83 polypeptides. To determine the correlation between the observed T-cell responses and antibody production to Lbhsp83. we compared the antibody (immunoglobulin G) reactivities to Lbhsp83 in sera from the three patient groups (Figure 12). The ELISA reactivities of ML patient sera with rLbhsp83a were comparable to those observed with parasite lysate, and in general, there was a direct correlation between ML patient anti- Lbhsp83 antibody titer and T-cell proliferation. Of 23 serum samples from ML patients analyzed, 22 were positive (-96%) with absorbance values of 0.20 to >3.0. Eleven of the ML patient semm samples had optical density values that were >1. In general, CL patients had significantly lower anti-Lbhsp83 antibody titers (x = 0.74; standard error of the mean [SEM] = 0.1) compared to those of ML patients. Therefore, ML and CL patient anti-rhsp83 antibody titers correlated with their respective T-cell proliferative responses. Anti-rLbhsp83 antibody titers were significantly higher in patients with ML (x = 1.5; SEM = 0.2) than in self-healing CL patients ( x = 0.35; SEM = 0.056), although their T-cell proliferative responses were similar. In fact, anti- Lbhsp83 antibody titers in semm from self-healing CL patients were comparable to those from uninfected controls (x = 0.24; SEM = 0.028). By using 2 standard deviations greater than the mean absorbance value of uninfected control (0.484) as a criterion for positive reactivity to Lbhsp83, eight of nine of the self-healing patient serum samples tested were negative. Example 4 Preparation of Clones Encoding Lt-210 This Example illustrates the preparation of clones encoding portions of the Leishmania antigen Lt-210, and which has the sequence provided in SEQ ID NO:8. An expression library was constructed from L tropica (MHOM/SA 91/WR1063C) genomic DNA. The DNA was isolated by solubilizing L. tropica promastigotes in lOmM Tris-HCl, pH 8.3, 50mM EDTA, 1% SDS and treating with lOOμg/ml RNaseA and lOOμg/ml proteinase K. The sample was then sequentially extracted with an equal volume of phenol, phenol: chloroform (1 :1), and Chloroform. DNA was precipitated by adding 0.1 volume of 3M sodium acetate (pH 5.2) and 2.5 volume 95% ethanol. The precipitate was resuspended in l OμM Tris, lmM EDTA. DNA was sheared by passage through a 30-gauge needle to a size range of 2-6 kilobase, and was repaired by incubation with DNA poll in the presence of 100 μ M each dATP, dCTP, dGTP, and dTTP. EcoRI adapters were ligated to the DNA fragments. After removal of unligated adapters by passage over a G-25 Sephadex™ column, the fragments were inserted in EcoRI cut Lambda ZapII (Stratagene, La Jolla, CA). Approximately 43,000 pfu were plated and screened with sera isolated from viscerotropic leishmaniasis (VTL) patients. Sera from VTL patients were received from Drs. M. Grogl and A. Magill. The VTL patient group included eight individuals from whom parasites were isolated and cultured, seven of which had confirmed infection with L. tropica. Four other patients were culture negative, but were still considered to be infected based on either PCR analysis or a positive monoclonal antibody smear (Dr. Max Grogl, personal communication). Semm samples from the 1 1 infected patients were pooled and anti-E. coli reactivity removed by affinity chromatography (Sambrook et al., supra, p. 12.27-12.28). Lambda phage expressing reactive proteins were detected after antibody binding by protein A-horseradish peroxidase and ABTS substrate. Three clones, Lt-1 , Lt-2, and Lt-3. containing a portion of the Lt-210 gene were identified and purified. The clones ranged in size from 1.4 to 3.3 kb and encoded polypeptides of 75 kD, 70 kD, and 120 kD, respectively. These three clones contain partial sequences of the Lt-210 gene. Lt-1 and Lt-2 are overlapping clones and were chosen for further study. The DNA sequences of Lt-1 and Lt-2 were determined. Exonuclease III digestion was used to create overlapping deletions of the clones (Heinikoff, Gene 25:351-359, 1984). Single strand template was prepared and the sequence determined with Applied Biosystems Automated Sequencer model 373A or by Sanger dideoxy sequencing. The sequence on both strands of the coding portion of Lt-1 clone was determined. The partial sequence of one strand of Lt-2 clone was determined. SEQ ID NO:7 presents the DNA sequence of Lt-1. and SEQ ID NO:8 provides the predicted amino acid sequence of the open reading frame. The DNA sequence of the coding portion of the Lt-1 clone includes a repeated nucleotide sequence at the 5' portion of the clone containing eight copies of a 99 bp repeat, three copies of a 60 bp repeat unit, which is part of the larger 99 bp repeat, and 800 bp of non-repeat sequence. The deduced amino acid sequence of the 99 bp repeat contains limited degeneracies. The mass of the predicted recombinant protein is 67,060 Daltons. A database search of PIR with the predicted amino acid sequence of the open reading frame yielded no significant homology to previously submitted sequences. Predicted secondary stmcture ofthe repeat portion ofthe clone is entirely α-helical. Sequence analysis of Lt-2 revealed that the 3' portion of the clone consisted of a mixture of 60 and 99 bp repeats that were identical, excepting occasional degeneracies, to the 60 and 99 bp repeats observed in Lt-1. Collectively, the sequencing data suggest that Lt-1 and Lt-2 are different portions of the same gene, Lt-2 being upstream of Lt-1, with possibly a small overlap. Hybridization analysis confirmed that rLt-2 and rLt-1 contain overlapping sequences. Genomic DNAs of various Leishmania species were restricted with a variety of enzymes, separated by agarose gel electrophoresis, and blotted on Nytran membrane filter (Schleicher & Schuell, Keene, NH). Inserts from rLt-1 and rLt- 2 were labeled with 3 P-CTP by reverse transcriptase from random oligonucleotide primers and used as probes after separation from unincoφorated nucleotides on a Sephadex G-50 column. Hybridizations using the rLt-1 or the rLt-2 probe are performed in 0.2M NaH PO 4 /3.6 M NaCl at 65°C. whereas hybridization using the rLt- lr probe is performed in 0.2 M NaH 2 PO 4 /3.6 M NaCl/0.2 M EDTA at 60°C ovemight. Filters are washed in 0.075 M NaCl/0.0075 M sodium citrate pH 7.0 (0.15 M NaCl/0.0150 M sodium citrate for the Lt-lr probe), plus 0.5% SDS at the same temperature as hybridization. Genomic DNA from a number of Leishmania species including L. tropica were analyzed by Southern blots as described above using the Lt-1. Lt-2, and Lt-lr inserts separately as probes. Collectively, various digests of L. tropica DNA indicate that this gene has a low copy number. A similar, overlapping pattem was observed using either the Lt-1 or Lt-2 insert as a probe, consistent with the premise that these two clones contain sequences near or overlapping one another. In addition, sequences hybridizing with these clones are present in other Leishmania species. L. tropica isolates have limited heterogeneity. Southern analyses of digested genomic DNA from four L tropica parasite strains isolated from VTL patients and three L. tropica parasite strains isolated from CL cases (two human, one canine) were performed. The Lt-lr insert described below was labeled and used as a probe. The seven different L. tropica isolates yielded similar intensities and restriction pattems, with only a single restriction fragment length polymoφhism among the isolates. These data, along with Southern analyses with additional enzymes, indicate limited heterogeneity in this region among the L. tropica isolates. The recombinant proteins of Lt-1 and Lt-2 were expressed and purified. The nested deletion set of Lt- 1 formed for sequencing included a clone referred to as Lt-lr, which contains one and one-third repeats. This polypeptide was also expressed and purified. In vivo excision of the pBluescript SK" phagemid from Lambda Zap II was performed according to the manufacturer's protocol. Phagemid vims particles were used to infect E. coli XL-1 Blue. Production of protein was induced by the addition of IPTG. Protein was recovered by first lysing pellets of induced bacteria in buffer (LB, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM ΕDTA) using a combination of lysozyme (750μg/mL) and sonication. rLt-1 , rLt-2, and rLt-lr. were recovered from the inclusion bodies after solubilization in 8M urea (rLt-1 and rLt-2) or 4M urea (rLt-lr). Proteins rLt-1 and rLt-2 were enriched and separated by precipitation with 25%-40% ammonium sulfate and rLt-lr was enriched by precipitation with 10%-25% ammonium sulfate. The proteins were further purified by preparative gel electrophoresis in 10% SDS-PAGΕ. Recombinant proteins were eluted from the gels and dialyzed in phosphate-buffered saline (PBS). Concentration was measured by the Pierce (Rockford, IL) BCA assay, and purity assessed by Coomassie blue staining after SDS- PAGE. Example 5 Preparation of LbeIF4A This example illustrates the molecular cloning of a DNA sequence encoding the L. braziliensis ribosomal antigen LbeIF4A. A genomic expression library was constmcted with sheared DNA from L. braziliensis (MHOM/BR/75/M2903) in bacteriophage λZAPII (Stratagene, La Jolla, CA). The expression library was screened with E. co//-preadsorbed patient sera from an L. braziliensis-infected individual with mucosal leishmaniasis. Plaques containing immunoreactive recombinant antigens were purified, and the pBSK(-) phagemid excised using the manufacturer's protocols. Nested deletions were performed with Exonuclease III to generate overlapping deletions for single stranded template preparations and sequencing. Single stranded templates were isolated following infection with VCSM13 helper phage as recommended by the manufacturer (Stratagene, La Jolla, CA) and sequenced by the dideoxy chain terminator method or by the Taq dye terminator system using the Applied Biosystems Automated Sequencer Model 373A. The immunoreactive recombinant antigens were then analyzed in patient T-cell assays for their ability to stimulate a proliferative and cytokine production, as described in Examples 7 and 8 below. A recombinant clone was identified in the above assays which, following sequence comparison of its predicted amino acid sequence with sequences of other proteins, was identified as a Leishmania braziliensis homolog of the eukaryotic initiation factor 4A (eIF4A). The isolated clone (pLeIF.1) lacked the first 48 amino acid residues (144 nucleotides) of the full length protein sequence. The pLeIF.1 insert was subsequently used to isolate the full length genomic sequence. SEQ ID NO:7 shows the entire nucleotide sequence of the full-length LbeIF4A polypeptide. The open reading frame (nucleotides 1 15 to 1323) encodes a 403 amino acid protein with a predicted molecular weight of 45.3 kD. A comparison of the predicted protein sequence of LbeIF4A with the homologous proteins from tobacco (TeIF4A), mouse (MeIF4A), and yeast (YeIF4A) shows extensive sequence homology, with the first 20-30 amino acids being the most variable. The lengths (403, 413, 407, and 395 amino acids), molecular weights (45.3, 46.8, 46.4, and 44.7 kDa), and isoelectric points (5.9, 5.4, 5.5, and 4.9) of LbeIF4A, TeIF4A, MeIF4A and YeIF4A, respectively, are similar. LbeIF4A shows an overall homology of 75.5% (57% identity, 18.5% conservative substitution) with TeIF4A, 68.6% (50% identity, 18.6% conservative substitution) with MeIF4A and 67.2% (47.6% identity, 19.6%) conservative substitution) with YeIF4A. Example 6 Preparation of Soluble Leishmania Antigens This Example illustrates the preparation of soluble Leishmania antigens from an L. major culture supematant. L. major promastigotes are grown to late log phase in complex medium with semm until the reach a density of 2-3 x IO 7 viable organisms per mL of medium. The organisms are thoroughly washed to remove medium components and resuspended at 2-3 x 10 7 viable organisms per mL of defined serum-free medium consisting of equal parts RPMI 1640 and medium 199, both from Gibco BRL, Gaithersburg, MD. After 8-12 hours, the supematant is removed, concentrated 10 fold and dialyzed against phosphate-buffered saline for 24 hours. Protein concentration is then determined and the presence of at least eight different antigens confirmed by SDS-PAGE. This mixture is referred to herein as "soluble Leishmania antigens." Example 7 Comparison of Interleukin-4 and Interferon-γ Production Stimulated bv Leishmania Antigens This Example illustrates the immunogenic properties of the antigens prepared according to Examples 1, 2, 5 and 6, as determined by their ability to stimulate IL-4 and IFN-γ in lymph node cultures from infected mice and in human PBMC preparations. Lymph node cultures for use in these studies were prepared from L major-infected BALB/c mice 10 days after infection, as described in Example 2. PBMC were prepared using peripheral blood obtained from individuals with cured L. donovani infections who were immunologically responsive to Leishmania. Diagnosis of the patients was made by clinical findings associated with at least one of the following: isolation of parasite from lesions, a positive skin test with Leishmania lysate or a positive serological test. Uninfected individuals were identified based on a lack of clinical signs or symptoms, a lack of history of exposure or travel to endemic areas, and the absence of a serological or cellular response to Leishmania antigens. Peripheral blood was collected and PBMC isolated by density centrifugation through Ficoll™ (Winthrop Laboratories, New York). Culture supematants were assayed for the levels of secreted IL-4 and IFN-γ. IFN-γ was quantitated by a double sandwich ELISA using mouse anti-human IFN-γ mAb (Chemicon, Temucula, CA) and polyclonal rabbit anti-human IFN-γ semm. Human rIFN-γ (Genentech Inc., San Francisco, CA) was used to generate a standard curve. IL-4 was quantitated in supematants by a double sandwich ELISA U5 ; ng a mouse anti-human IL-4 mAb (Ml) and a polyclonal rabbit anti-human IL-4 sera (P3). Human IL-4 (Immunex Coφ., Seattle, WA) was used to generate a standard curve ranging from 50 pg/ml to 1 ng/ml. Figures 13A and 13B, illustrate the mean level of secreted IL-4 and IFN- γ. respectively, 72 hours after addition of 10 μg/mL of each of the following antigens to a lymph node culture prepared as described above: soluble Leishmania antigen (i.e., an extract prepared from mptured promastigotes which contains membrane and intemal antigens (SLA)), Ldp23, LbeIF4A (LeIF), Lbhsp83, M15 and LmelF (the L. major homolog of LbeIF4A). The levels of secreted IL-4 and IFN-γ in medium alone (i.e., unstimulated) are also shown. While SLA elicits a predominantly Th2 response from lymph node cells of Leishmania-infected mice. Ldp23, LbeIF4A, Lbhsp83 and Ml 5 elicited relatively little IL-4 and large amounts of IFN-γ, consistent with a Thi response profile. Figure 14 shows the level of secreted IFN-γ in culture filtrate from infected and uninfected human PBMC preparations 72 hours after addition of 10 μg/mL L. major lysate, Ml 5 or L-Rack, an immunodominant leishmanial antigen in murine leishmaniasis. Similarly, Figure 15 illustrates the level of secreted IFN-γ in culture filtrate from infected and uninfected human PBMC preparations 72 hours after addition of lOμg/mL L. major lysate, soluble Leishmania antigens (prepared as described in Example 6) or L-Rack. These results indicate that Ml 5 and soluble Leishmania antigens, but not L:-Rack, are potent stimulators of IFN-γ production in patient PBMC, but not in PBMC obtained from uninfected individuals. Thus. Ml 5 and soluble Leishmania antigens elicit a dominant Thi cytokine profile in both mice and humans infected with Leishmania. Example 8 Comparison of Proliferation Stimulated bv Leishmania Antigens This Example illustrates the immunogenic properties of the antigens prepared according to Examples 1. 2, 5 and 6, as determined by their ability to stimulate proliferation in lymph node cultures from infected mice and in human PBMC preparations. For in vitro proliferation assays, 2 - 4 x IO 3 cells/well were cultured in complete medium (RPMI 1640 supplemented with gentamycin, 2-ME, L-glutamine, and 10%) screened pooled A+ human semm; Trimar, Hollywood, CA) in 96-well flat bottom plates with or without 10 μg/ml of the indicated antigens or 5 μg/ml PHA (Sigma Immunochemicals, St. Louis, MO) for five days. The cells were then pulsed with 1 μCi of [^H] thymidine for the final 18 hours of culture. Figure 16 illustrates the proliferation observed after addition of 10 μg/mL or 20 μg/mL of each ofthe following antigens to a lymph node culture prepared as described in Example 7: SLA, Ldp23, LbeIF4A, Lbhsp83, and M15. The level of proliferation without the addition of antigen is also shown. Data are represented as mean cpm. These results demonstrate that a variety of leishmanial antigens are capable of stimulatory lymph node cell proliferation from Leishmania-infected mice. Figures 17 and 18 illustrate the proliferation observed in human PBMC preparations from Leishmania-i mune and uninfected individuals following the addition of 10 μg/mL Ml 5 and soluble Leishmania antigens, respectively. These values are compared to the proliferation observed following the addition of culture medium, L. major lysate or L-Rack. The results show that M15 and soluble Leishmania antigens stimulate proliferation in Leishmania-immune PBMC, but not in PBMC obtained from uninfected individuals, demonstrating that Ml 5 and soluble antigens (but not L-Rack) are recognized by PBMC from individuals immune to Leishmania due to a previous infection. From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the puφose of illustration, various modifications may be made without deviating from the spirit and scope ofthe invention. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Reed. Steven G. Campos-Neto. Antomo Webb. John R. Dillon. Davin C. Skeiky. Yasir A.W. (π) TITLE OF INVENTION' LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS (in) NUMBER OF SEQUENCES: 10 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: SEED and BERRY (B) STREET: 6300 Columbia Center. 701 Fifth Avenue (C) CITY: Seattle (D) STATE: Washington (E) COUNTRY: USA (F) ZIP: 98104-7092 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible • (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0. Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US (B) FILING DATE: 22-SEP-1995 ( C ) CLASSIFICATION : ( vm ) ATTORNEY /AGENT INFORMATION : (A) NAME- Maki, David J. (B) REGISTRATION NUMBER: 31.392 (C) REFERENCE/DOCKET NUMBER: 210121.420 (i ) TELECOMMUNICATION INFORMATION (A) TELEPHONE. (206) 622-4900 (B) TELEFAX (206) 682-6031 (C) TELEX 3723836 SEEDANDBERRY (2) INFORMATION FOR SEQ ID NO 1 (') SEQUENCE CHARACTERISTICS (A) LENGTH 3134 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS. single (D) TOPOLOGY linear (ι>. FEATURE (A) NAME/KEY- CDS (B) LOCATION 421 2058 (xi) SEQUENCE DESCRIPTION SkEQ ID NO.l CAAGTGTCGA AGGACAGTGT TCNCCGTGTG AGATCGCCGG CTGTGCGTGT GAAGGCGGTG 60 CCATCGGANA AACAACACCG GTGGANCCGC AGGAAACCAT CTTTCTCCGC AGGTCTCTTT 120 TTGTTGTCGA TTGAGAGTGC NCCAAACCCT GCTGGTGCCC TTCTCACATA TCATGTTTT7 180 CGTTGTGCGC TCGCTTTGCC TTTCCTCTCC TTTCCCTCTC TTCCGTGGTG CCGTGTATAC 240 πCTGGCACC CGCTACGTCA CTTCGCTGGT TTGAACAGAA CCACTGTGAA CACCCACGGG 300 CGATCGCACA CATACACATC CCTCACTCAC ACACACAGCT ACATCTATCC TACATAAAGC 360 TGAAAAAAAA GTCTACGAAC AATTTTGTTT TTACAGTGCG TTGCCGCACA TTTCTCCGTA 420 ATG GAC GCA ACT GAG CTG AAG AAC AAG GGG AAC GAA GAG TTC TCC GCC 468 Met Asp Ala Thr Glu Leu Lys Asn Lys Gly Asn Glu Glu Phe Ser Ala 1 5 10 15 GGC CGC TAT GTG GAG GCG GTG AAC TAC TTC TCA AAG GCG ATC CAG TTG 516 Gly Arg Tyr Val Glu Ala Val Asn Tyr Phe Ser Lys Ala He Gin Leu 20 25 30 GAT GAG CAG AAC AGT GTC CTC TAC AGC AAC CGC TCC GCC TGT TTT GCA 564 Asp Glu Gin Asn Ser Val Leu Tyr Ser Asn Arg Ser Ala Cys Phe Ala 35 40 45 GCC ATG CAG AAA TAC AAG GAC GCG CTG GAC GAC GCC GAC AAG TGC ATC 612 Ala Met Gin Lys Tyr Lys Asp Ala Leu Asp Asp Ala Asp Lys Cys He 50 55 60 TCG ATC AAG CCG AAT TGG GCC AAG GGC TAC GTG CGC CGA GGA GCA GCT 660 Ser He Lys Pro Asn Trp Ala Lys Gly Tyr Val Arg Arg Gly Ala Ala 65 70 75 80 CTC CAT GGC ATG CGC CGC TAC GAC GAT GCC ATT GCC GCG TAT GAA AAG 708 Leu His Gly Met Arg Arg Tyr ASD Asp Ala He Ala Ala Tyr Glu Lys 85 90 95 GGG CTC AAG GTG GAC CCT TCC AAC AGC GGC TGC GCG CAG GGC GTG AAG 756 Gly Leu Lys Val Asp Pro Ser Asn Ser Gly Cys Ala Gin Gly Val Lys 100 105 110 GAC GTG CAG GTA GCC AAG GCC CGC GAA GCA CGT GAC CCC ATC GCT CGC 804 Asp Val Gin Val Ala Lys Ala Arg Glu Ala Arg Asp Pro He Ala Arg 115 120 125 GTC TTC ACC CCG GAG GCG TTC CGC AAG ATC CAA GAG AAT CCC AAG CTG 852 Val Phe Thr Pro Glu Ala Phe Arg Lys He Gin Glu Asn Pro Lys Leu 130 135 140 TCT CTA CTT ATG CTG CAG CCG GAC TAC GTG AAG ATG GTA GAC ACC GTC 900 Ser Leu Leu Met Leu Gin Pro Asp Tyr Val Lys Met Val Asp Thr Val 145 150 155 160 ATC CGC GAC CCT TCG CAG GGC CGG CTG TAC ATG GAA GAC CAG CGC TTT 948 He Arg Asp Pro Ser Gin Gly Arg Leu Tyr Met Glu Asp Gin Arg Phe 165 170 175 GCC CTG ACG CTC ATG TAC CTG AGC GGA ATG AAG ATT CCC AAC GAT GGT 996 Ala Leu Thr Leu Met Tyr Leu Ser Gly Met Lys He Pro Asn Asp Gly 180 185 190 GAT GGC GAG GAG GAG GAA CGT CCG TCT GCG AAG GCG GCA GAG ACA GCG 1044 Asp Gly Glu Glu Glu Glu Arg Pro Ser Ala Lys Ala Ala Glu Thr Ala 195 200 205 AAG CCA AAA GAG GAG AAG CCT CTC ACC GAC AAC GAG AAG GAG GCC CTG 1092 Lys Pro Lys Glu Glu Lys Pro Leu Thr Asp Asn Glu Lys Glu Ala Leu 210 215 220 GCG CTC AAG GAG GAG GGC AAC AAG CTG TAC CTC TCG AAG AAG TTT GAG 1140 Ala Leu Lys Glu Glu Gly Asn Lys Leu Tyr Leu Ser Lys Lys Phe Glu 225 230 235 240 GAG GCG CTG ACC AAG TAC CAA GAG GCG CAG GTG AAA GAC CCC AAC AAC 1188 Glu Ala Leu Thr Lys Tyr Gin Glu Ala Gin Val Lys Asp Pro Asn Asn 245 250 255 ACT HA TAC Aπ CTG AAC GTG TCG GCC GTG TAC TTC GAG CAG GGT GAC 1236 Thr Leu Tyr He Leu Asn Val Ser Ala Val Tyr Phe Glu Gin Gly Asp 260 265 270 TAC GAC AAG TGC ATC GCC GAG TGC GAG CAC GGT ATC GAG CAC GGT CGC 1284 Tyr Asp Lys Cys He Ala Glu Cys Glu His Gly He Glu His Gly Arg 275 280 285 GAG AAC CAC TGC GAC TAC ACA ATC ATT GCG AAG CTC ATG ACC CGG AAC 1332 Glu Asn His Cys Asp Tyr Thr He He Ala Lys Leu Met Thr Arg Asn 290 295 300 GCC TTG TGC CTC CAG AGG CAG AGG AAG TAC GAG GCT GCT ATC GAC CTT 1380 Ala Leu Cys Leu Gin Arg Gin Arg Lys Tyr Glu Ala Ala He Asp Leu 305 310 315 320 TAC AAG CGC GCC CTT GTC GAG TGG CGT AAC CCT GAC ACC CTC AAG AAG 1428 Tyr Lys Arg Ala Leu Val Glu Trp Arg Asn Pro Asp Thr Leu Lys Lys 325 330 335 CTG ACG GAG TGC GAG AAG GAG CAC CAA AAG GCG GTG GAG GAA GCC TAC 1476 Leu Thr Glu Cys Glu Lys Glu His Gin Lys Ala Val Glu Glu Ala Tyr 340 345 350 ATC GAT CCT GAG ATC GCG AAG CAG AAG AAA GAC GAA GGT AAC CAG TAC 1524 He Asp Pro Glu He Ala Lys Gin Lys Lys Asp Glu Gly Asn Gin Tyr 355 360 365 πC AAG GAG GAT AAG TTC CCC GAG GCC GTG GCA GCG TAC ACG GAG GCC 1572 Phe Lys Glu Asp Lys Phe Pro Glu Ala Val Ala Ala Tyr Thr Glu Ala 370 375 380 ATC AAG CGC AAC CCT GCC GAG CAC ACC TCC TAC AGC AAT CGC GCG GCC 1620 He Lys Arg Asn Pro Ala Glu His Thr Ser Tyr Ser Asn Arg Ala Ala 385 390 395 400 GCG TAC ATC AAG CTT GGA GCC TTC AAC GAC GCC CTC AAG GAC GCG GAG 1668 Ala Tyr He Lys Leu Gly Ala Phe Asn Asp Ala Leu Lys Asp Ala Glu 405 410 415 AAG TGC ATT GAG CTG AAG CCC GAC TTT GTT AAG GGC TAC GCG CGC AAG 1716 Lys Cys He Glu Leu Lys Pro Asp Phe Val Lys Gly Tyr Ala Arg Lys 420 425 430 GGT CAT GCT TAC TTT TGG ACC AAG CAG TAC AAC CGC GCG CTG CAG GCG 1764 Gly His Ala Tyr Phe Trp Thr Lys Gin Tyr Asn Arg Ala Leu Gin Ala 435 440 445 TAC GAT GAG GGC CTC AAG GTG GAC CCG AGC AAT GCG GAC TGC AAG GAT 1812 Tyr Asp Glu Gly Leu Lys Val Asp Pro Ser Asn Ala Asp Cys Lys Asp 450 455 460 GGG CGG TAT CGC ACA ATC ATG AAG ATT CAG GAG ATG GCA TCT GGC CAA 1860 Gly Arg Tyr Arg Thr He Met Lys He Gin Glu Met Ala Ser Gly Gin 465 470 475 480 TCC GCG GAT GGC GAC GAG GCG GCG CGC CGG GCC ATG GAC GAT CCT GAA 1908 Ser Ala Asp Gly Asp Glu Ala Ala Arg Arg Ala Met Asp Asp Pro Glu 485 490 495 ATC GCG GCA ATC ATG CAA GAT AGC TAC ATG CAA CTA GTG TTG AAG GAG 1956 He Ala Ala He Met Gin Asp Ser Tyr Met Gin Leu Val Leu Lys Glu 500 505 510 ATG CAG AAC GAT CCC ACG CGC ATT CAG GAG TAC ATG AAG GAC TCC GGG 2004 Met Gin Asn Asp Pro Thr Arg He Gin Glu Tyr Met Lys Asp Ser Gly 515 520 525 ATC TCA TCG AAG ATC AAC AAG CTG ATT TCA GCT GGC ATC ATT CGT TTT 2052 He Ser Ser Lys He Asn Lys Leu He Ser Ala Gly He He Arg Phe 530 535 540 GGT CAG TAGACTTCTA CGCTGCCTCA TCTTTTCCGT GTCTTTGCGT CGGCGGGTAT 2108 Gly Gin 545 CGTAAAGCAC AATAAAGCAG CGATTCACAT GCACGAGTAA AGTGCTGCGC CTCTCAAACA 2168 CGACGTCGAG GCTGTGGTGC AGATGCGCGT CCTGCATGAA GGTAGTGAAG AGGAAAGTAA 2228 GGGATGTTGT TTGTGGGCCT TCGTGGCTGC GCACACACCT CTTATCTCCT TCGCTTGGTA 2288 CCTTCTCCCT TTTTCGTCπ CACCCCCCTT TCTCπCTCA CGCTCTCCCT GGCGCGGTGG 2348 TGCAACGATT TCGTTTTATT TACGTCTGTG TAGCTCCTCT ATTCAACGGT GCGATGACGC 2408 TAACGAAGCT GGCCTGTATT CGGCTAAG3C GAAGGCAAAA GACTAGGAGG GGGGGGGGAA 2468 GGAGACGGCG TGACCATCAC TGCGAAGAAA CAAGCCGAAG AAAAGGCCCC GAACGCCTGC 2528 ATTTCCGCGC GCCCTCGCCC GCCTTCCTTC CTTCCTTCGC TCTCTCTCTC TCTCTCTCTC 2588 GCTATCTTCT CAACGGAGAC ATGAAAGGCG TTTGTTAGGA AAAGAGGGGG GGGGGAAGAG 2648 TGGGACGACG CGCTGCGTCT TTTGGGCACT GGTCACGTGC GTCACCCTCT TTTTTTATCT 2708 CTATTGGCAC TGTCTTGTTT CTTTTCCCTT TCCTATCATA CGCGTCTCGC AAACGACTCC 2768 GCGCTGAGCA GCCATGTGCT GCGGCGTGGA GGAAGTACAC AGACATCACG GATGCATATG 2828 TGCGCGTCCG TGTACGCGCT TGTATGGGGC TTCTAACAGC GCCTGTGTGT GTTTGTGTGT 2888 GTGTGTGTGT GTGTGTCTGT GTATTTCGAG CGTCTGTATG CTATTCTATT AAGCACCGAA 2948 GAAGAGACAC ACACGACAGC GAAGGAGATG GTGTCGGCTT TTCGGCTAAT CACTCCCTTC 3008 CATAGCTTCT CTGAAGGAGG CTCTCTTCCA GAGGAATAGA CTGCAGATGG GGTCCACGTT 3068 TATCTGAGGA GTCAACGGAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3128 CTCGAG 3134 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 546 ammo acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (n) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Asp Ala Thr Glu Leu Lys Asn Lys Gly Asn Glu Glu Phe Ser Ala 1 5 10 15 Gly Arg Tyr Val Glu Ala Val Asn Tyr Phe Ser Lys Ala He Gin Leu 20 25 30 Asp Glu Gin Asn Ser Val Leu Tyr Ser Asn Arg Ser Ala Cys Phe Ala 35 40 45 Ala Met Gin Lys Tyr Lys Asp Ala Leu Asp Asp Ala Asp Lys Cys He 50 55 60 Ser He Lys Pro Asn Trp Ala Lys Gly Tyr Val Arg Arg Gly Ala Ala 65 70 75 80 Leu His Gly Met Arg Arg Tyr Asp Asp Ala He Ala Ala Tyr Glu Lys 85 90 95 Gly Leu Lys Val Asp Pro Ser Asn Ser Gly Cys Ala Gin Gly Val Lys 100 105 110 Asp Val Gin Val Ala Lys Ala Arg Glu Ala Arg Asp Pro He Ala Arg 115 120 125 Val Phe Thr Pro Glu Ala Phe Arg Lys He Gin Glu Asn Pro Lys Leu 130 135 140 Ser Leu Leu Met Leu Gin Pro Asp Tyr Val Lys Met Val Asp Thr Val 145 150 155 160 He Arg Asp Pro Ser Gin Gly Arg Leu Tyr Met Glu Asp Gin Arg Phe 165 170 175 Ala Leu Thr Leu Met Tyr Leu Ser Gly Met Lys He Pro Asn Asp Gly 180 185 190 Asp Gly Glu Glu Glu Glu Arg Pro Ser Ala Lys Ala Ala Glu Thr Ala 195 200 205 Lys Pro Lys Glu Glu Lys Pro Leu Thr Asp Asn Glu Lys Glu Ala Leu 210 215 220 Ala Leu Lys Glu Glu Gly Asn Lys Leu Tyr Leu Ser Lys Lys Phe Glu 225 230 235 240 Glu Ala Leu Thr Lys Tyr Gin Glu Ala Gin Val Lys Asp Pro Asn Asn 245 250 255 Thr Leu Tyr He Leu Asn Val Ser Ala Val Tyr Phe Glu Gin Gly Asp 260 265 270 Tyr Asp Lys Cys He Ala Glu Cys Glu His Gly He Glu His Gly Arg 275 280 285 Glu Asn His Cys Asp Tyr Thr He He Ala Lys Leu Met Thr Arg Asn 290 295 300 Ala Leu Cys Leu Gin Arg Gin Arg Lys Tyr Glu Ala Ala He Asp Leu 305 310 315 320 Tyr Lys Arg Ala Leu Val Glu Trp Arg Asn Pro Asp Thr Leu Lys Lys 325 330 335 Leu Thr Glu Cys Glu Lys Glu His Gin Lys Ala Val Glu Glu Ala Tyr 340 345 350 He Asp Pro Glu He Ala Lys Gin Lys Lys Asp Glu Gly Asn Gin Tyr 355 360 365 Phe Lys Glu Asp Lys Phe Pro Glu Ala Val Ala Ala Tyr Thr Glu Ala 370 375 380 He Lys Arg Asn Pro Ala Glu His Thr Ser Tyr Ser Asn Arg Ala Ala 385 390 395 400 Ala Tyr He Lys Leu Gly Ala Phe Asn Asp Ala Leu Lys Asp Ala Glu 405 410 415 Lys Cys He Glu Leu Lys Pro Asp Phe Val Lys Gly Tyr Ala Arg Lys 420 425 430 Gly His Ala Tyr Phe Trp Thr Lys Gin Tyr Asn Arg Ala Leu Gin Ala 435 44C 445 Tyr Asp Glu Gly Leu Lys Val Aso Pro Ser Asn Ala Asp Cys Lys Asp 450 455 460 Gly Arg Tyr Arg Thr He Met Lys He Gin Glu Met Ala Ser Gly Gin 465 470 475 480 Ser Ala Asp Gly Asp Glu Ala Ala Arg Arg Ala Met Asp Asp Pro Glu 485 490 495 He Ala Ala He Met Gin Asp Ser Tyr Met Gin Leu Val Leu Lys Glu 500 505 510 Met Gin Asn Asp Pro Thr Arg He Gin Glu Tyr Met Lys Asp Ser Gly 515 520 525 He Ser Ser Lys He Asn Lys Leu He Ser Ala Gly He He Arg Phe 530 535 540 Gly Gin 545 (2) INFORMATION FOR SEQ ID N0:3. (ι) SEQUENCE CHARACTERISTICS: (A) LENGTH: 676 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 26..550 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AATTCGGCAC GAGGCAπGT GCATA ATG GTC AAG TCC CAC TAC ATC TGC GCG 52 Met Val Lys Ser His Tyr He Cys Ala 550 555 GGC CGC CTG GTG CGC ATC CTG CGT GGC CCC CGC CAG GAC CGC GTT GGT 100 Gly Arg Leu Val Arg He Leu Arg Gly Pro Arg Gin Asp Arg Val Gly 560 565 570 GTG ATC GTC GAC ATT GTC GAC GCG AAC CGC GTG CTG GTG GAG AAC CCG 148 Val He Val Asp He Val Asp Ala Asn Arg Val Leu Val Glu Asn Pro 575 580 585 GAG GAC GCG AAG ATG TGG CGC CAC GTG CAG AAC CTG AAG AAC GTG GAG 196 Glu Asp Ala Lys Met Trp Arg His Val Gin Asn Leu Lys Asn Val Glu 590 595 600 CCG CTG AAG TAC TGC GTG AGC GTC AGC CGC AAC TGC AGC GCG AAG GCG 244 Pro Leu Lys Tyr Cys Val Ser Val Ser Arg Asn Cys Ser Ala Lys Ala 605 610 615 CTG AAG GAT GCG CTG GCC TCG TCG AAG GCG CTG GAG AAG TAC GCG AAG 292 Leu Lys Asp Ala Leu Ala Ser Ser Lys Ala Leu Glu Lys Tyr Ala L s 620 625 630 ACG CGC ACT GCT GCG CGC GTG GAG GCG AAG AAG GCG TGC GCC GCG TCG 340 Thr Arg Thr Ala Ala Arg Val Glu Ala Lys Lys Ala Cys Ala Ala Ser 640 645 650 ACG GAC TTC GAG CGC TAC CAG CTG CGC GTT GCG CGC CGT TCT CGC GCG 388 Thr Asp Phe Glu Arg Tyr Gin Leu Arg Val Ala Arg Arg Ser Arg Ala 655 660 665 CAC TGG GCG CGC AAG GTG TTC GAC GAG AAG GAC GCG AAG ACG CCC GTG 436 His Trp Ala Arg Lys Val Phe Asp Glu Lys Asp Ala Lys Thr Pro Val 670 675 680 TCG TGG CAC AAG GTT GCG CTG AAG AAG ATG CAG AAG AAG GCC GCA AAG 484 Ser Trp His Lys Val Ala Leu Lys Lys Met Gin Lys Lys Ala Ala Lys 685 690 695 ATG GAC TCG ACC GAG GGC GCT AAG AGG CGC ATG CAG AAG GCG ATC GCT 532 Met Asp Ser Thr Glu Gly Ala Lys Arg Arg Met Gin Lys Ala He Ala 700 705 710 715 GCC CGC AAG GCG AAA AAG TAAGGCCATA CCCTCACπC GCπGπTCG 580 Ala Arg Lys Ala Lys Lys 720 TGATTTTTCG TGGGAGTCGG TGGCCCTACC AGCGGTCTπ CAπGGCπA TTTCTATCCG 640 GTCTGAAAGA GGTACAAAAA AAAAAAAAAA AAAAAA 676 (2) INFORMATION FOR SEQ ID NO:4- (l) SEQUENCE CHARACTERISTICS. (A) LENGTH: 175 ammo acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4- Met Val Lys Ser His Tyr He Cys Ala Gly Arg Leu Val Arg He Leu 1 5 10 15 Arg Gly Pro Arg Gin Asp Arg Val Gly Val He Val Asp He Val Asp 20 25 30 Ala Asn Arg Val Leu Val Glu Asn Pro Glu Asp Ala Lys Met Trp Arg 35 40 45 His Val Gin Asn Leu Lys Asn Val Glu Pro Leu Lys Tyr Cys Val Ser 50 55 60 Val Ser Arg Asn Cys Ser Ala Lys Ala Leu Lys Asp Ala Leu Ala Ser 65 70 75 80 Ser Lys Ala Leu Glu Lys Tyr Ala Lys Thr Arg Thr Ala Ala Arg Val 85 90 95 Glu Ala Lys Lys Ala Cys Ala Ala Ser Thr Asp Phe Glu Arg Tyr Gin 1O0 105 110 Leu Arg Val Ala Arg Arg Ser Arg Ala His Trp Ala Arg Lys Val Phe 115 120 125 Asp Glu Lys Asp Ala Lys Thr Pro Val Ser Trp His Lys Val Ala Leu 130 135 140 Lys Lys Met Gin Lys Lys Ala Ala Lys Met Asp Ser Thr Glu Gly Ala 145 150 155 160 Lys Arg Arg Met Gin Lys Ala He Ala Ala Arg Lys Ala Lys Lys 165 170 175 (2) INFORMATION FOR SEQ ID NO:5 (ι) SEQUENCE CHARACTERISTICS (A) LENGTH: 2040 base pairs (B) TYPE- nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY, linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 62..2029 (xi) SEQUENCE DESCRIPTION- SEQ ID N0:5: CGCGGTGGCG GCCGCTCTAG AACTAGTGGA TCCCCCGGGC TGCAGGAAπ CGGCACGAGA 60 G AGC CTG ACG GAC CCG GCG GTG CTG GGC GAG GAG ACT CAC CTG CGC 106 Ser Leu Thr Asp Pro Ala Val Leu Gly Glu Glu Thr His Leu Arg 180 185 190 GTC CGC GTG GTG CCG GAC AAG GCG AAC AAG ACG CTG ACG GTG GAG GAT 154 Val Arg Val Val Pro Asp Lys Ala Asn Lys Thr Leu Thr Val Glu Asp 195 200 205 AAC GGC ATC GGC ATG ACC AAG GCG GAC CTC GTG AAC AAT CTG GGC ACG 202 Asn Gly He Gly Met Thr Lys Ala Asp Leu Val Asn Asn Leu Gly Thr 210 215 220 ATC GCG CGC TCC GGC ACG AAG GCT TTC ATG GAG GCA CTG GAG GCC GGC 250 He Ala Arg Ser Gly Thr Lys Ala Phe Met Glu Ala Leu Glu Ala Gly 225 230 235 GGC GAC ATG AGC ATG ATC GGC CAG TTC GGT GTC GGC πc TAC TCC GCG 298 Gly Asp Met Ser Met He Gly Gin Phe Gly Val Gly Phe Tyr Ser Ala 240 245 250 TAC CTT GTG GCG GAC CGC GTG ACG GTG GTG TCG AAG AAC AAC TCG GAC 346 Tyr Leu Val Ala Asp Arg Val Thr Val Val Ser Lys Asn Asn Ser Asp 255 260 265 270 GAG GCG TAC TGG GAA TCG TCT GCG GGG GGC ACG TTC ACC ATC ACG AGC 394 Glu Ala Tyr Trp Glu Ser Ser Ala Gly Gly Thr Phe Thr He Thr Ser 275 280 285 GTG CAG GAG TCG GAC ATG AAG CGC GGC ACG AGT ACA ACG CTG CAC CTA 442 Val Gin Glu Ser Asp Met Lys Arg Gly Thr Ser Thr Thr Leu His Leu 290 295 300 AAG GAG GAC CAG CAG GAG TAC CTG GAG GAG CGC CGG GTG AAG GAG CTG 490 Lys Glu Asp Gin Gin Glu Tyr Leu Glu Glu Arg Arg Val Lys Glu Leu 305 310 315 ATC AAG AAG CAC TCC GAG TTC ATC GGC TAC GAC ATC GAG CTG ATG GTG 538 He Lys Lys His Ser Glu Phe He Gly Tyr Asp He Glu Leu Met Val 320 325 330 GAG AAG ACG GCG GAG AAG GAG GTG ACG GAC GAG GAC GAG GAG GAG GAC 586 Glu Lys Thr Ala Glu Lys Glu Val Thr Asp Glu Asp Glu Glu Glu Asp 335 340 345 350 GAG TCG AAG AAG AAG TCC TGC GGG GAC GAG GGC GAG CCG AAG GTG GAG 634 Glu Ser Lys Lys Lys Ser Cys Gly Asp Glu Gly Glu Pro Lys Val Glu 355 360 365 GAG GTG ACG GAG GGC GGC GAG GAC AAG AAG AAG AAG ACG AAG AAG GTG 682 Glu Val Thr Glu Gly Gly Glu Asp Lys Lys Lys Lys Thr Lys Lys Val 370 375 380 AAG GAG GTG AAG AAG ACG TAC GAG GTC AAG AAC AAG CAC AAG CCG CTC 730 Lys Glu Val Lys Lys Thr Tyr Glu Val Lys Asn Lys His Lys Pro Leu 385 390 395 TGG ACG CGC GAC ACG AAG GAC GTG ACG AAG GAG GAG TAC GCG GCC TTC 776 Trp Thr Arg Asp Thr Lys Asp Val Thr Lys Glu Glu Tyr Ala Ala Phe 400 405 410 TAC AAG GCC ATC TCC AAC GAC TGG GAG GAC ACG GCG GCG ACG AAG CAC 826 Tyr Lys Ala He Ser Asn Asp Trp Glu Asp Thr Ala Ala Thr Lys His 415 420 425 430 πC TCG GTG GAG GGC CAG CTG GAG πc CGC GCG ATC GCG TTC GTG CCG 874 Phe Ser Val Glu Gly Gin Leu Glu Phe Arg Ala He Ala Phe Val Pro 435 440 445 AAG CGC GCG CCG πc GAC ATG TTC GAG CCG AAC AAG AAG CGC AAC AAC 922 Lys Arg Ala Pro Phe Asp Met Phe Glu Pro Asn Lys Lys Arg Asn Asn 450 455 460 ATC AAG CTG TAC GTG CGC CGC GTG πc ATC ATG GAC AAC TGC GAG GAC 970 He Lys Leu Tyr Val Arg Arg Val Phe He Met Asp Asn Cys Glu Asp 465 470 475 CTG TGC CCG GAC TGG CTC GGC TTC GTG AAG GGC GTC GTG GAC AGC GAG 1018 Leu Cys Pro Asp Trp Leu Gly Phe Val Lys Gly Val Val Asp Ser Glu 480 485 490 GAC CTG CCG CTG AAC ATC TCG CGC GAG AAC CTG CAG CAG AAC AAG ATC 1066 Asp Leu Pro Leu Asn He Ser Arg Glu Asn Leu Gin Gin Asn Lys He 495 500 505 510 CTG AAG GTG ATC CGC AAG AAC ATC GTG AAG AAG TGC CTG GAG CTG πc 1114 Leu Lys Val He Arg Lys Asn He Val Lys Lys Cys Leu Glu Leu Phe 515 520 525 GAA GAG ATA GCG GAG AAC AAG GAG GAC TAC AAG CAG TTC TAC GAG CAG 1162 Glu Glu He Ala Glu Asn Lys Glu Asp Tyr Lys Gin Phe Tyr Glu Gin 530 535 540 πC GGC AAG AAC ATC AAG CTG GGC ATC CAC GAG GAC ACG GCG AAC CGC 1210 Phe Gl Lys Asn He Lys Leu Gly He His Glu Asp Thr Ala Asn Arg 545 550 555 AAG AAG CTG ATG GAG πG CTG CGC πC TAC AGC ACC GAG TCG GGG GAG 1258 Lys Lys Leu Met Glu Leu Leu Arg Phe Tyr Ser Thr Glu Ser Gly Glu 560 565 570 GAG ATG ACG ACA CTG AAG GAC TAC GTG ACG CGC ATG AAG CCG GAG CAG 1306 Glu Met Thr Thr Leu Lys Asp Tyr Val Thr Arg Met Lys Pro Glu Gin 575 580 585 590 AAG TCG ATC TAC TAC ATC ACT GGC GAC AGC AAG AAG AAG CTG GAG TCG 1354 Lys Ser He Tyr Tyr He Thr Gly Asp Ser Lys Lys Lys Leu Glu Ser 595 600 605 TCG CCG TTC ATC GAG AAG GCG AGA CGC TGC GGG CTC GAG GTG CTG TTC 1402 Ser Pro Phe He Glu Lys Ala Arg Arg Cys Gly Leu Glu Val Leu Phe 610 615 620 ATG ACG GAG CCG ATC GAC GAG TAC GTG ATG CAG CAG GTG AAG GAC TTC 1450 Met Thr Glu Pro He Asp Glu Tyr Val Met Gin Gin Val Lys Asp Phe 625 630 635 GAG GAC AAG AAG TTC GCG TGC CTG ACG AAG GAA GGC GTG CAC TTC GAG 1498 Glu Asp Lys Lys Phe Ala Cys Leu Thr Lys Glu Gly Val His Phe Glu 640 645 650 GAG TCC GAG GAG GAG AAG AAG CAG CGC GAG GAG AAG AAG GCG GCG TGC 1546 Glu Ser Glu Glu Glu Lys Lys Gin Arg Glu Glu Lys Lys Ala Ala Cys 655 660 665 670 GAG AAG CTG TGC AAG ACG ATG AAG GAG GTG CTG GGC GAC AAG GTG GAG 1594 Glu Lys Leu Cys Lys Thr Met Lys Glu Val Leu Gly Asp Lys Val Glu 675 680 685 AAG GTG ACC GTG TCG GAG CGC CTG TTG ACG TCG CCG TGC ATC CTG GTG 1642 Lys Val Thr Val Ser Glu Arg Leu Leu Thr Ser Pro Cys He Leu Val 690 695 700 ACG TCG GAG TTT GGG TGG TCG GCG CAC ATG GAA CAG ATC ATG CGC AAC 1690 Thr Ser Glu Phe Gly Trp Ser Ala His Met Glu Gin He Met Arg Asn 705 710 715 CAG GCG CTG CGC GAC TCC AGC ATG GCG CAG TAC ATG GTG TCC AAG AAG 1738 Gin Ala Leu Arg Asp Ser Ser Met Ala Gin Tyr Met Val Ser Lys Lys 720 725 730 ACG ATG GAG GTG AAC CCC GAC CAC CCC ATC ATC AAG GAG CTG CGC CGC 1786 Thr Met Glu Val Asn Pro Asp His Pro He He Lys Glu Leu Arg Arg 735 740 745 750 CGC GTG GAG GCG GAC GAG AAC GAC AAG GCC GTG AAG GAC CTC GTC πc 1834 Arg Val Glu Ala Asp Glu Asn Asp Lys Ala Val Lys Asp Leu Val Phe 755 760 765 CTG CTC TTC GAC ACG TCG CTG CTC ACG TCC GGC πC CAG CTG GAT GAC 1882 Leu Leu Phe Asp Thr Ser Leu Leu Thr Ser Gly Phe Gin Leu Asp Asp 770 775 780 CCC ACC GGC TAC GCC GAG CGC ATC AAC CGC ATG ATC AAG CTC GGC CTG 1930 Pro Thr Gly Tyr Ala Glu Arg He Asn Arg Met He Lys Leu Gly Leu 785 790 795 TCG CTC GAC GAG GAG GAG GAG GAG GTC GCC GAG GCG CCG CCG GCC GAG 1978 Ser Leu Asp Glu Glu Glu Glu Glu Val Ala Glu Ala Pro Pro Ala Glu 800 805 810 GCA GCC CCC GCG GAG GTC ACC GCC GGC ACC TCC AGC ATG GAG CAG GTG 2026 Ala Ala Pro Ala Glu Val Thr Ala Gly Thr Ser Ser Met Glu Gin Val 815 820 825 830 GAC TGAGCCGGTA A 2040 Asp (2) INFORMATION FOR SEQ ID N0:6: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 656 am o acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Ser Leu Thr Asp Pro Ala Val Leu Gly Glu Glu Thr His Leu Arg Val 1 5 10 15 Arg Val Val Pro Asp Lys Ala Asn Lys Thr Leu Thr Val Glu Asp Asn 20 25 30 Gly He Gly Met Thr Lys Ala Asp Leu Val Asn Asn Leu Gly Thr He 35 40 45 Ala Arg Ser Gly Thr Lys Ala Phe Met Glu Ala Leu Glu Ala Gly Gly 50 55 60 Asp Met Ser Met He Gly Gin Phe Gly Val Gly Phe Tyr Ser Ala Tyr 65 70 75 80 Leu Val Ala Asp Arg Val Thr Val Val Ser Lys Asn Asn Ser Asp Glu 85 90 95 Ala Tyr Trp Glu Ser Ser Ala Gly Gly Thr Phe Thr He Thr Ser Val 100 105 110 Gin Glu Ser Asp Met Lys Arg Gly Thr Ser Thr Thr Leu His Leu Lys 115 120 125 Glu Asp Gin Gin Glu Tyr Leu Glu Glu Arg Arg Val Lys Glu Leu He 130 135 140 Lys Lys His Ser Glu Phe He Gly Tyr Asp He Glu Leu Met Val Glu 145 150 155 160 Lys Thr Ala Glu Lys Glu Val Thr Asp Glu Asp Glu Glu Glu Asp Glu 165 170 175 Ser Lys Lys Lys Ser Cys Gly Asp Glu Gly Glu Pro Lys Val Glu Glu 180 185 190 Val Thr Glu Gly Gly Glu Asp Lys Lys Lys Lys Thr Lys Lys Val Lys 195 200 205 Glu Val Lys Lys Thr Tyr Glu Val Lys Asn Lys His Lys Pro Leu Trp 210 215 220 Thr Arg Asp Thr Lys Asp Val Thr Lys Glu Glu Tyr Ala Ala Phe Tyr 225 230 235 240 Lys Ala He Ser Asn Asp Trp Glu Asp Thr Ala Ala Thr Lys His Phe 245 250 255 Ser Val Glu Gly Gin Leu Glu Phe Arg Ala He Ala Phe Val Pro Lys 260 265 270 Arg Ala Pro Phe Asp Met Phe Glu Pro Asn Lys Lys Arg Asn Asn He 275 280 285 Lys Leu Tyr Val Arg Arg Val Phe He Met Asp Asn Cys Glu Asp Leu 290 295 300 Cys Pro Asp Trp Leu Gly Phe Val Lys Gly Val Val Asp Ser Glu Asp 305 310 315 320 Leu Pro Leu Asn He Ser Arg Glu Asn Leu Gin Gin Asn Lys He Leu 325 330 335 Lys Val He Arg Lys Asn He Val Lys Lys Cys Leu Glu Leu Phe Glu 340 345 350 Glu He Ala Glu Asn Lys Glu Asp Tyr Lys Gin Phe Tyr Glu Gin Phe 355 360 365 Gly Lys Asn He Lys Leu Gly He His Glu Asp Thr Ala Asn Arg Lys 370 375 380 Lys Leu Met Glu Leu Leu Arg Phe Tyr Ser Thr Glu Ser Gly Glu Glu 385 390 395 400 Met Thr Thr Leu Lys Asp Tyr Val Thr Arg Met Lys Pro Glu Gin Lys 405 410 415 Ser He Tyr Tyr He Thr Gly Asp Ser Lys Lys Lys Leu Glu Ser Ser 420 425 430 Pro Phe He Glu Lys Ala Arg Arg Cys Gly Leu Glu Val Leu Phe Met 435 440 445 Thr Glu Pro He Asp Glu Tyr Val Met Gin Gin Val Lys Asp Phe Glu 450 455 460 Asp Lys Lys Phe Ala Cys Leu Thr Lys Glu Gly Val His Phe Glu Glu 465 470 475 480 Ser Glu Glu Glu Lys Lys Gin Arg Glu Glu Lys Lys Ala Ala Cys Glu 485 490 495 Lys Leu Cys Lys Thr Met Lys Glu Val Leu Gly Asp Lys Val Glu Lys 500 505 510 Val Thr Val Ser Glu Arg Leu Leu Thr Ser Pro Cys He Leu Val Thr 515 520 525 Ser Glu Phe Gly Trp Ser Ala His Met Glu Gin He Met Arg Asn Gin 530 535 540 Ala Leu Arg Asp Ser Ser Met Ala Gin Tyr Met Val Ser Lys Lys Thr 545 550 555 560 Met Glu Val Asn Pro Asp His Pro He He Lys Glu Leu Arg Arg Arg 565 570 575 Val Glu Ala Asp Glu Asn Asp Lys Ala Val Lys Asp Leu Val Phe Leu 580 585 590 Leu Phe Asp Thr Ser Leu Leu Thr Ser Gly Phe Gin Leu Asp Asp Pro 595 600 605 Thr Gly Tyr Ala Glu Arg He Asn Arg Met He Lys Leu Gly Leu Ser 610 615 620 Leu Asp Glu Glu Glu Glu Glu Val Ala Glu Ala Pro Pro Ala Glu Ala 625 630 635 640 Ala Pro Ala Glu Val Thr Ala Gly Thr Ser Ser Met Glu Gin Val Asp 645 650 655 (2) INFORMATION FOR SEQ ID NO:7: (ι) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1771 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1698 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CAG GCC CGC GTC CAG GCC CTC GAG GAG GCA GCG CGT CTC CGC GCG GAG 48 Gin Ala Arg Val Gin Ala Leu Glu Glu Ala Ala Arg Leu Arg Ala Glu 1 5 10 15 CTG GAG GCG GCC GAG GAG GCG GCC CGC CTG GAT GTC ATG CAT GCG GCC 96 Leu Glu Ala Ala Glu Glu Ala Ala Arg Leu Asp Val Met His Ala Ala 20 25 30 GAG CAG GCC CGT GTC CAG GCC CTC GAG GAG GCA GCG CGT CTC CGC GCG 144 Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala Ala Arg Leu Arg Ala 35 40 45 GAG CTG GAG GAG GCC GAG GAG GCG GCC CGC CTG GAT GTC ATG CAT GCG 192 Glu Leu Glu Glu Ala Glu Glu Ala Ala Arg Leu Asp Val Met His Ala 50 55 60 GCC GAG CAG GCC CGC GTC CAG GCC CTC GAG GAG GCA GCG CGT CTC CGC 240 Ala Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala Ala Arg Leu Arg 65 70 75 80 GCG GAG CTG GAG GCT GCC GAG GAG GCG GCG CGC CTG GAG GCC ATG CAC 288 Ala Glu Leu Glu Ala Ala Glu Glu Ala Ala Arg Leu Glu Ala Met His 85 90 95 GAG GCC GAG CAG GCC CGC TCC CAG GCC CTC GAG GAG GCA GCG CGT CTC 336 Glu Ala Glu Gin Ala Arg Ser Gin Ala Leu Glu Glu Ala Ala Arg Leu 100 105 110 CGC GCG GAG CTG GAG GAA GCC GAG GAG GCG GCC CGC CTG GAT GTC ATG 384 Arg Ala Glu Leu Glu Glu Ala Glu Glu Ala Ala Arg Leu Asp Val Met 115 120 125 CAT GCG GCC GAG CAG GCC CGC GTC CAG GCC CTC GAG GAG GCA GCG CGT 432 His Ala Ala Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala Ala Arg 130 135 140 CTC CGC GCG GAG CTG GAG GAG GCC GAG GAG GCG GCC CGC CTG GAG GCC 480 Leu Arg Ala Glu Leu Glu Glu Ala Glu Glu Ala Ala Arg Leu Glu Ala 145 150 155 160 ATG CAC GAG GCC GAG CAG GCC CGC TCC CAG GCC CTC GAG GAG GCA GCG 528 Met His Glu Ala Glu Gin Ala Arg Ser Gin Ala Leu Glu Glu Ala Ala 165 170 175 CGT CTC CGC GCG GAG CTG GAG GCG GCC GAG GAG GCG GCC CGC CTG GAT 576 Arg Leu Arg Ala Glu Leu Glu Ala Ala Glu Glu Ala Ala Arg Leu Asp 180 185 190 GTC ATG CAC GAG GCC GAG CAG GCC CGT GTC CAG GCC CTC GAG GAG GCG 624 Val Met His Glu Ala Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala 195 200 205 GCG CGC CTG GAT GTC ATG CAC GAG GCC GAG CAG GCC CGC GTC CAG GCC 672 Ala Arg Leu Asp Val Met His Glu Ala Glu Gin Ala Arg Val Gin Ala 210 215 220 CTC GAG GAG GCA GCG CGT CTC CGC GCG GAG CTG GAG GCG GCC GAG GAG 720 Leu Glu Glu Ala Ala Arg Leu Arg Ala Glu Leu Glu Ala Ala Glu Glu 225 230 235 240 GCG GCC CGC CTG GAT GTC ATG CAC GAG GCC GAG CAG GCC CGC GTC CAG 768 Ala Ala Ar Leu Asp Val Met His Glu Ala Glu Gin Ala Arg Val Gin 245 250 255 GCC CTC GAG GAG GCA GCG CGT CTC CGC GCG GAG CTG GAG GCG GCC GAG 816 Ala Leu Glu Glu Ala Ala Arg Leu Arg Ala Glu Leu Glu Ala Ala Glu 260 265 270 GAG GCG GCC CGC CTG GAT GTC ATG CAC GAG GGC GAG CAG GCC CGT GTC 864 Glu Ala Ala Arg Leu Asp Val Met His Glu Gly Glu Gin Ala Arg Val 275 280 285 CAG GCC CTC GAG GAG GCG GCC CGC CTG GAG GCC ATG CAC GAG GCC GAG 912 Gin Ala Leu Glu Glu Ala Ala Arg Leu Glu Ala Met His Glu Ala Glu 290 295 300 CAG GCC CGC TCC CAG GCC CTC GAG GAG GCA GCG CGT CTC TGC GCG GAG 960 Gin Ala Arg Ser Gin Ala Leu Glu Glu Ala Ala Arg Leu Cys Ala Glu 305 310 315 320 CTG GAG GCT GAG GAG GAG GAA AAA GAT GAG CGG CCG GCG ACG TCG AGC 1008 Leu Glu Ala Glu Glu Glu Glu Lys Asp Glu Arg Pro Ala Thr Ser Ser 325 330 335 TAC AGC GAG GAG TGC AAA GGG CGA CTG CTA TCG AGG GCG CGG CCG GAT 1056 Tyr Ser Glu Glu Cys Lys Gly Arg Leu Leu Ser Arg Ala Arg Pro Asp 340 345 350 CCG CGG AGG CCG CTG CCG CGG CCG TTC ATT GGG ATG TCA CTG TTG GAG 1104 Pro Arg Arg Pro Leu Pro Arg Pro Phe He Gly Met Ser Leu Leu Glu 355 360 365 GAT GTG GAG AAG AGT ATT CTC ATT GTG GAC GGG CTC TAC AGG GAT GGG 1152 Asp Val Glu Lys Ser He Leu He Val Asp Gly Leu Tyr Arg Asp Gly 370 375 380 CCG GCG TAC CAG ACG GGC ATC CGC CTC GGG GAT GTC CTC TTG CGT ATC 1200 Pro Ala Tyr Gin Thr Gly He Arg Leu Gly Asp Val Leu Leu Arg He 385 390 395 400 GCG GGG GTT TAC GTG GAT TCA ATA GCG AAG GCG AGG CAG GTG GTC GAT 1248 Ala Gly Val Tyr Val Asp Ser He Ala Lys Ala Arg Gin Val Val Asp 405 410 415 GCG CGT TGC CGC TGC GGC TGC GTC GTT CCC GTG ACG CTG GCG ACG AAG 1296 Ala Arg Cys Arg Cys Gly Cys Val Val Pro Val Thr Leu Ala Thr Lys 420 425 430 ATG AAC CAG CAG TAC AGC GTG GCT CTG TAT ATC ATG ACG GTG GAT CCG 1344 Met Asn Gin Gin Tyr Ser Val Ala Leu Tyr He Met Thr Val Asp Pro 435 440 445 CAG CAC AAC GAC AAG CCC Tπ Tπ Tπ GAT GTG CAC ATC CAC CAC CGC 1392 Gin His Asn Asp Lys Pro Phe Phe Phe Asp Val His He His His Arg 450 455 460 ATC GAG AGC TCG CAC ATG GGG AAG AAG GCG CAG TGG ATG GAA GTT CTT 1440 He Glu Ser Ser His Met Gly Lys Lys Ala Gin Trp Met Glu Val Leu 465 470 475 480 GAG AGC CCA TCC GTA TCT TCG GCT GCC ACC ACC CCT CTC GTG CCG CTC 1488 Glu Ser Pro Ser Val Ser Ser Ala Ala Thr Thr Pro Leu Val Pro Leu 485 490 495 πG CGT GAG CCG ACG CCG CGT AGG GGC TCA GAG CTG CAG TCA AGT GCT 1536 Leu Arg Glu Pro Thr Pro Arg Arg Gly Ser Glu Leu Gin Ser Ser Ala 500 505 510 CGT TCC GCC TTC GTT GCC ACG TCT TAC TTC TCG AGC GCG CGC AGG TCG 1584 Arg Ser Ala Phe Val Ala Thr Ser Tyr Phe Ser Ser Ala Arg Arg Ser 515 520 525 GTC AGC TCA GAA AGT GAG CGA CCG CGC GGG TCC TCT AGC GTG GCT ATG 1632 Val Ser i> p r Glu Ser Glu Arg Pro Arg Gly Ser Ser Ser Val Ala Met 530 535 540 GCG GAG GAG GCG ATC GCG CTG GCG CCG CAA GGG TAT ACC CCA CCC AAC 1680 Ala Glu Glu Ala He Ala Leu Ala Pro Gin Gly Tyr Thr Pro Pro Asn 545 550 555 560 CAA GTG CGC GGC CGT AGT TGACGTCTCT GTGTGAGTGT GTGTCGCTCC 1728 Gin Val Arg Gly Arg Ser 565 GTCTCCTTCC ππTCGTCA TGTGππAT TCATTTCTΓT TTC 1771 (2) INFORMATION FOR SEQ ID NO 8 (ι) SEQUENCE CHARACTERISTICS (A) LENGTH 566 amino acids (B) TYPE amino acid (D) TOPOLOGY linear (n) MOLECULE TYPE protein (xi) SEQUENCE DESCRIPTION SEQ ID NO 8 Gin Ala Arq Val Gin Ala Leu Glu Glu Ala Ala Arg Leu Arq Ala Glu Leu Glu Ala Ala Glu Glu Ala Ala Arg Leu Asp Val Met His Ala Ala 20 25 30 Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala Ala Arg Leu Arg Ala 35 40 45 Glu Leu Glu Glu Ala Glu Glu Ala Ala Arg Leu Asp Val Met His Ala 50 55 60 Ala Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala Ala Arq Leu Arg 65 70 75 80 Ala Glu Leu Glu Ala Ala Glu Glu Ala Ala Arg Leu Glu Ala Met His 85 90 95 Glu Ala Glu Gin Ala Arg Ser Gin Ala Leu Glu Glu Ala Ala Arg Leu 100 105 110 Arg Ala Glu Leu Glu Glu Ala Glu Glu Ala Ala Arg Leu Asp Val Met 115 120 125 His Ala Ala Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala Ala Arg 130 135 140 Leu Arg Ala Glu Leu Glu Glu Ala Glu Glu Ala Ala Arg Leu Glu Ala 145 150 155 160 Met His Glu Ala Glu Gin Ala Arg Ser Gin Ala Leu Glu Glu Ala Ala 165 170 175 Arg Leu Arg Ala Glu Leu Glu Ala Ala Glu Glu Ala Ala Arg Leu Asp 180 185 190 Val Met His Glu Ala Glu Gin Ala Arg Val Gin Ala Leu Glu Glu Ala 195 200 205 Ala Arg Leu Asp Val Met His Glu Ala Glu Gin Ala Arg Val Gin Ala 210 215 220 Leu Glu Glu Ala Ala Arg Leu Arq Ala Glu Leu Glu Ala Ala Glu Glu 225 230 235 240 Ala Ala Arg Leu Aso Val Met His Glu Ala Glu Gin Ala Arg Val Gin 245 250 255 Ala Leu Glu Glu Ala Ala Arg Leu Arg Ala Glu Leu Glu Ala Ala Glu 260 265 270 Glu Ala Ala Arg Leu Asp Val Met His Glu Gly Glu Gin Ala Arg Val 275 280 285 Gin Ala Leu Glu Glu Ala Ala Arg Leu Glu Ala Met His Glu Ala Glu 290 295 300 Gin Ala Arg Ser Gin Ala Leu Glu Glu Ala Ala Arg Leu Cys Ala Glu 305 310 315 320 Leu Glu Ala Glu Glu Glu Glu Lys Asp Glu Arg Pro Ala Thr Ser Ser 325 330 335 Tyr Ser Glu Glu Cys Lys Gly Arg Leu Leu Ser Arg Ala Arg Pro Asp 340 345 350 Pro Arg Arg Pro Leu Pro Arg Pro Phe He Gly Met Ser Leu Leu Glu 355 360 365 Asp Val Glu Lys Ser He Leu He Val Asp Gly Leu Tyr Arg Asp Gly 370 375 380 Pro Ala Tyr Gin Thr Gly He Arg Leu Gly Asp Val Leu Leu Arq lie 385 390 395 400 Ala Gly Val Tyr Val Asp Ser He Ala Lys Ala Arg Gin Val Val Asp 405 410 415 Ala Arg Cys Arg Cys Gly Cys Val Val Pro Val Thr Leu Ala Thr Lys 420 425 430 Met Asn Gin Gin Tyr Ser Val Ala Leu Tyr He Met Thr Val Asp Pro 435 440 445 Gin His Asn Asp Lys Pro Phe Phe Phe Asp Val His He His His Arg 450 455 460 He Glu Ser Ser His Met Gly Lys Lys Ala Gin Trp Met Glu Val Leu 465 470 475 480 Glu Ser Pro Ser Val Ser Ser Ala Ala Thr Thr Pro Leu Val Pro Leu 485 490 495 Leu Arg Glu Pro Thr Pro Arg Arg Gly Ser Glu Leu Gin Ser Ser Ala 500 505 510 Arg Ser Ala Phe Val Ala Thr Ser Tyr Phe Ser Ser Ala Arg Arg Ser 515 520 525 Val Ser Ser Glu Ser Glu Arg Pro Arg Gly Ser Ser Ser Val Ala Met 530 535 540 Ala Glu Glu Ala He Ala Leu Ala Pro Gin Gly Tyr Thr Pro Pro Asn 545 550 555 560 Gin Val Arg Gly Arg Ser 565 (2) INFORMATION FOR SEQ ID NO 9 (l) SEQUENCE CHARACTERISTICS. (A) LENGTH. 1618 base pairs (B) TYPE- nucleic acid (C) STRANDEDNESS. single (D) TOPOLOGY, linear (ii) MOLECULE TYPE cDNA (ix) FEATURE (A) NAME/KEY. CDS (B) LOCATION: 115..1323 ( xi ) SEQUENCE DESCRIPTION: SEQ ID N0:9 - CCACTCTCTC GGTCGTCTGT CTCCCACGCG CGCACGCAGT TGATTTCCGC CTTCπAAAC 60 GCTCTCπTT ππTATTTT TCACCTGACC AACCGCACCA CGTCGGCCTC CATC ATG 117 Met 1 TCG CAG CAA GAC CGA GTT GCC CCA CAG GAC CAG GAC TCG TTC CTC GAC 165 Ser Gin Gin Asp Arg Val Ala Pro Gin Asp Gin Asp Ser Phe Leu Asp 5 10 15 GAC CAG CCC GGC GTC CGC CCG ATC CCG TCC πC GAT GAC ATG CCG TTG 213 Asp Gin Pro Gly Val Arg Pro He Pro Ser Phe Asp Asp Met Pro Leu 20 25 30 CAC CAG AAC CTT CTG CGC GGC ATC TAC TCG TAC GGC TTC GAG AAA CCG 261 His Gin Asn Leu Leu Arg Gly He Tyr Ser Tyr Gly Phe Glu Lys Pro 35 40 45 TCC AGC ATC CAG CAG CGC GCC ATC GCC CCC TTC ACG CGC GGC GGC GAC 309 Ser Ser He Gin Gin Arg Ala He Ala Pro Phe Thr Arg Gly Gly Asp 50 55 60 65 ATC ATC GCG CAG GCG CAG TCC GGT ACC GGC AAG ACG GGC GCC πc TCC 357 He He Ala Gin Ala Gin Ser Gly Thr Gly Lys Thr Gly Ala Phe Ser 70 75 80 He Gly Leu Leu Gin Arg Leu Asp Phe Arg His Asn Leu He Gin Gly 85 90 95 CTC GTG CTC TCC CCG ACC CGC GAG CTG GCC CTG CAG ACG GCG GAG GTG 453 Leu Val Leu Ser Pro Thr Arg Glu Leu Ala Leu Gin Thr Ala Glu Val 100 105 110 ATC AGC CGC ATC GGC GAG TTC CTG TCG AAC AGC GCG AAG πc TGT GAG 501 He Ser Arg He Gly Glu Phe Leu Ser Asn Ser Ala Lys Phe Cys Glu 115 120 125 ACC TTT GTG GGT GGC ACG CGC GTG CAG GAT GAC CTG CGC AAG CTG CAG 549 Thr Phe Val Gly Gly Thr Arg Val Gin Asp Asp Leu Arg Lys Leu Gin 130 135 140 145 GCT GGC GTC GTC GTC GCC GTG GGG ACG CCG GGC CGC GTG TCC GAC GTG 597 Ala Gly Val Val Val Ala Val Gly Thr Pro Gly Arg Val Ser Asp Val 150 155 160 ATC AAG CGC GGC GCG CTG CGC ACC GAG TCC CTG CGC GTG CTG GTG CTC 645 He Lys Arg Gly Ala Leu Arg Thr Glu Ser Leu Arg Val Leu Val Leu 165 170 175 GAC GAG GCT GAT GAG ATG CTG TCT CAG GGC TTC GCG GAT CAG ATT TAC 693 Asp Glu Ala Asp Glu Met Leu Ser Gin Gly Phe Ala Asp Gin He Tyr 180 185 190 GAG ATC TTC CGC TTC CTG CCG AAG GAC ATC CAG GTC GCG CTC πc TCC 741 Glu He Phe Arg Phe Leu Pro Lys Asp He Gin Val Ala Leu Phe Ser 195 200 205 GCC ACG ATG CCG GAG GAG GTG CTG GAG CTG ACA AAG AAG πc ATG CGC 789 Ala Thr Met Pro Glu Glu Val Leu Glu Leu Thr Lys Lys Phe Met Arg 210 215 220 225 GAC CCC GTA CGC ATT CTC GTG AAG CGC GAG AGC CTG ACG CTG GAG GGC 837 Asp Pro Val Arg He Leu Val Lys Arg Glu Ser Leu Thr Leu Glu Gly 230 235 240 ATC AAG CAG TTC TTC ATC GCC GTC GAG GAG GAG CAC AAG CTG GAC ACG 885 He Lys Gin Phe Phe He Ala Val Glu Glu Glu His Lys Leu Asp Thr 245 250 255 CTG ATG GAC CTG TAC GAG ACC GTG TCC ATC GCG CAG TCC GTC ATC TTC 933 Leu Met Asp Leu Tyr Glu Thr Val Ser He Ala Gin Ser Val lie Phe 260 265 270 GCC AAC ACC CGC CGC AAG GTG GAC TGG ATC GCC GAG AAG CTG AAT CAG 981 Ala Asn Thr Arg Arg Lys Val ASP Trp He Ala Glu Lys Leu Asn Gin 275 280 285 AGC AAC CAC ACC GTC AGC AGC ATG CAC GCC GAG ATG CCC AAG AGC GAC 1029 Ser Asn His Thr Val Ser Ser Met His Ala Glu Met Pro Lys Ser Asp 290 295 300 305 CGC GAG CGC GTC ATG AAC ACC TTC CGC AGC GGC AGC TCC CGC GTG CTC 1077 Arg Glu Arg Val Met Asn Thr Phe Arg Ser Gly Ser Ser Arg Val Leu 310 315 320 GTA ACG ACC GAC CTC GTG GCC CGC GGC ATC GAC GTG CAC CAC GTG AAC 1125 Val Thr Thr Asp Leu Val Ala Arg Gly He Asp Val His His Val Asn 325 330 335 ATC GTC ATC AAC TTC GAC CTG CCG ACG AAC AAG GAG AAC TAC CTG CAC 1173 He Val He Asn Phe Asp Leu Pro Thr Asn Lys Glu Asn Tyr Leu His 340 345 350 CGC ATT GGC CGC GGC GGC CGC TAC GGC GTA AAG GGT GTT GCC ATC AAC 1221 Arg He Gly Arg Gly Gly Arg Tyr Gly Val Lys Gly Val Ala He Asn 355 360 365 TTC GTG ACG GAG AAA GAC GTG GAG CTG CTG CAC GAG ATC GAG GGG CAC 1269 Phe Val Thr Glu Lys Asp Val Glu Leu Leu His Glu He Glu Gly His 370 375 380 385 TAC CAC ACG CAG ATC GAT GAG CTC CCG GTG GAC πT GCC GCC TAC CTC 1317 Tyr His Thr Gin He Asp Glu Leu Pro Val Asp Phe Ala Ala Tyr Leu 390 395 400 GGC GAG TGA GCGGGCCCCT GCCCCCCπC CCTGCCCCCC TCTCGCGACG 1366 Gly Glu AGAGAACGCA CATCGTAACA CAGCCACGCG AACGATAGTA AGGGCGTGCG GCGGCGπCC 1426 CCTCCTCCTG CCAGCGGCCC CCCTCCGCAG CGCπCTCπ πGAGAGGGG GGCAGGGGGA 1486 GGCGCTGCGC CTGGCTGGAT GTGTGCπGA GCπGCAπC CGTCAAGCAA GTGCTTTGπ 1546 TTAATTATGC GCGCCGTTTT GπGCTCGTC CCTπCGTTG GTGπππC GGCCGAAACG 1606 GCGπTAAAG CA 1618 (2) INFORMATION FOR SEQ ID NO:10: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH- 403 am o acids (B) TYPE, amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protem (xi) SEQUENCE DESCRIPTION: SEQ ID N0:10: Met Ser Gin Gin Asp Arg Val Ala Pro Gin Asp Gin Asp Ser Phe Leu 1 5 10 15 Asp Asp Gin Pro Gly Val Arg Pro He Pro Ser Phe Asp Asp Met Pro 20 25 30 Leu His Gin Asn Leu Leu Arg Gly He Tyr Ser Tyr Gly Phe Glu Lys 35 40 45 Pro Ser Ser He Gin Gin Arg Ala He Ala Pro Phe Thr Arg Gly Gly 50 55 60 Asp He He Ala Gin Ala Gin Ser Gly Thr Gly Lys Thr Gly Ala Phe 65 70 75 80 Ser He Gly Leu Leu Gin Arg Leu Asp Phe Arg His Asn Leu He Gin 85 90 95 Gly Leu Val Leu Ser Pro Thr Arg Glu Leu Ala Leu Gin Thr Ala Glu 1O0 105 110 Val He Ser Arg He Gly Glu Phe Leu Ser Asn Ser Ala Lys Phe Cys 115 120 125 Glu Thr Phe Val Gly Gly Thr Arg Val Gin Asp Asp Leu Arg Lys Leu 130 135 140 Gin Ala Gly Val Val Val Ala Val Gly Thr Pro Gly Arg Val Ser Asp 145 150 155 160 Val He Lys Arg Gly Ala Leu Arg Thr Glu Ser Leu Arg Val Leu Val 165 170 175 Leu Asp Glu Ala Asp Glu Met Leu Ser Gin Gly Phe Ala Asp Gin He 180 185 190 Tyr Glu He Phe Arg Phe Leu Pro Lys Asp He Gin Val Ala Leu Phe 195 200 205 Ser Ala Thr Met Pro Glu Glu Val Leu Glu Leu Thr Lys Lys Phe Met 210 215 220 Arg Asp Pro Val Arg He Leu Val Lys Arg Glu Ser Leu Thr Leu Glu 225 230 235 240 Gly He Lys Gin Phe Phe He Ala Val Glu Glu Glu His Lys Leu Asp 245 250 255 Thr Leu Met Asp Leu Tyr Glu Thr Val Ser He Ala Gin Ser Val He 260 265 270 Phe Ala Asn Thr Arg Arg Lys Val Asp Trp He Ala Glu Lys Leu Asn 275 280 285 Gin Ser Asn His Thr Val Ser Ser Met His Ala Glu Met Pro Lys Ser 290 295 300 Asp Arg Glu Arg Val Met Asn Thr Phe Arg Ser Gly Ser Ser Arg Val 305 310 315 320 Leu Val Thr Thr Asp Leu Val Ala Arg Gly He Asp Val His His Val 325 330 335 Asn He Val lie Asn Phe Asp Leu Pro Thr Asn Lys Glu Asn Tyr Leu 340 345 350 His Arg He Gly Arg Gly Gly Arg Tyr Gly Val Lys Gly Val Ala He 355 360 365 Asn Phe Val Thr Glu Lys Asp Val Glu Leu Leu His Glu He Glu Gly 370 375 380 His Tyr His Thr Gin He Asp Glu Leu Pro Val Asp Phe Ala Ala Tyr 385 390 395 400 Leu Gly Glu

Claims: Claims 1. A polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:2, or a variant of said antigen that differs only in conservative substitutions and/or modifications. 2. The polypeptide of claim 1 , comprising amino acids 1 - 564 of SEQ ID NO:2. 3. An isolated DNA molecule comprising a nucleotide sequence encoding a polypeptide according to claim 1. 4. The DNA molecule of claim 3 wherein the nucleotide sequence is selected from the group consisting of: (a) nucleotides 421 through 2058 of SEQ ID NO: 1 ; and (b) DNA sequences that hybridize to a nucleotide sequence complementary to nucleotides 421 through 2058 of SEQ ID NO: l under moderately stringent conditions. 5. A recombinant expression vector comprising the DNA molecule of claim 3. 6. A host cell transformed or transfected with the expression vector of claim 5. 7. A polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:4, or a variant of said antigen that differs only in conservative substitutions and/or modifications. 8. The polypeptide of claim 7, comprising amino acids 1-175 of SEQ ID NO:4. 9. An isolated DNA molecule comprising a nucleotide sequence encoding a polypeptide according to claim 7. 10. The DNA molecule of claim 9 wherein the nucleotide sequence is selected from the group consisting of: (a) nucleotides 25 through 549 of SEQ ID NO:3; and (b) DNA sequences that hybridize to a nucleotide sequence complementary to nucleotides 25 through 549 of SEQ ID NO:3 under moderately stringent conditions. 1 1. A recombinant expression vector comprising the DNA molecule of claim 9. 12. A host cell transformed or transfected with the expression vector of claim 1 13. A pharmaceutical composition comprising a polypeptide according to claim 1 and a physiologically acceptable carrier. 14. A pharmaceutical composition comprising a polypeptide according to claim 7 and a physiologically acceptable carrier. 15. A pharmaceutical composition comprising at least two different polypeptides selected from the group consisting of: (a) a polypeptide according to claim 1 ; (b) a polypeptide according to claim 7; (c) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:6. or a variant of said antigen that differs only in conservative substitutions and/or modifications; (d) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:8, or a variant of said antigen that differs only in conservative substitutions and/or modifications; and (e) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO: 10, or a variant of said antigen that differs only in conservative substitutions and/or modifications; and a physiologically acceptable carrier. 16. A pharmaceutical composition according to any one of claims 13-15 further comprising soluble Leishmania antigens. 17. A pharmaceutical composition comprising soluble Leishmania antigens and a physiologically acceptable carrier. 18. A vaccine comprising a polypeptide according to claim 1 and a non¬ specific immune response enhancer. 19. A vaccine comprising a polypeptide according to claim 7 and a non¬ specific immune response enhancer. 20. A vaccine comprising at least two different polypeptides selected from the group consisting of: (a) a polypeptide according to claim 1 ; (b) a polypeptide according to claim 7; (c) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:6, or a variant of said antigen that differs only in conservative substitutions and/or modifications; (d) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO:8, or a variant of said antigen that differs only in conservative substitutions and/or modifications; and (e) a polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO: 10, or a variant of said antigen that differs only in conservative substitutions and/or modifications; and a non-specific immune response enhancer. 21. A vaccine according to any one of claims 18-20. further comprising soluble Leishmania antigens. 22. A vaccine comprising soluble Leishmania antigens and a non-specific immune response enhancer. 23. A vaccine according to any one of claims 18-20 or 22 wherein the non¬ specific immune response enhancer is an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO: 10, or a variant of said antigen that differs only in conservative substitutions and/or modifications. 24. A vaccine according to any one of claims 18-20 or 22 further comprising a delivery vehicle. 25. The vaccine of claim 24 wherein the delivery vehicle is a biodegradable microsphere. 26. A pharmaceutical composition according to any one of claims 13-15 or 17, for use in the manufacture of a medicament for inducing protective immunity against leishmaniasis in a patient. 27. A vaccine according to any one of claims 18-20 or 22, for use in the manufacture of a medicament for inducing protective immunity against leishmaniasis in a patient. 28. The composition of claim 26 wherein the leishmaniasis is caused by a Leishmania species selected from the group consisting of L. donovani. L. chagasi, L. infantum, L. major, L. amazonensis, L. braziliensis, L. panamensis, L. tropica and L. guyanensis. 29. The vaccine of claim 27 wherein the leishmaniasis is caused by a Leishmania species selected from the group consisting of L. donovani, L. chagasi, L. infantum, L. major, L. amazonensis, L. braziliensis, L. panamensis, L. tropica and L. guyanensis. 30. A method for detecting Leishmania infection in a patient, comprising: (a) contacting dermal cells of a patient with a pharmaceutical composition according to any one of claims 13-15 or 17; and (b) detecting an immune response on the patient's skin, and therefrom detecting Leishmania infection in the patient. 31. The method of claim 30 wherein the immune response is induration. 32. A diagnostic kit comprising: (a) a pharmaceutical composition according to any one of claims 13-15 or 17; and (b) apparatus sufficient to contact dermal cells of a patient with the pharmaceutical composition. 33. A pharmaceutical composition according to any one of claims 13- 15 or 17, for use in the manufacture of a medicament for stimulating a cellular and/or humoral immune response in a patient. 34. The composition of claim 33 wherein said response is a Thi immune response. 35. The composition of claim 33 wherein said response is IL-12 production. 36. A vaccine according to any one of claims 18-20 or 22, for use in the manufacture of a medicament for stimulating a cellular and/or humoral immune response in a patient. 37. The vaccine of claim 36 wherein said response is a Thi response. 38. The vaccine of claim 36 wherein said response is IL-12 production. 39. A pharmaceutical composition according to any one of claims 13-15 or 17, for use in the manufacture of a medicament for treating a patient afflicted with a disease responsive to IL-12 stimulation. 40. A vaccine according to any one of claims 18-20 or 22, for use in the manufacture of a medicament for treating a patient afflicted with a disease responsive to IL- 12 stimulation.

Inventors: CAMPOS-NETO ANTONIO, DILLON DAVIN C, REED STEVEN G, SKEIKY YASIR A W, WEBB JOHN R, CAMPOS-NETO, ANTONIO, DILLON, DAVIN, C., REED, STEVEN, G., SKEIKY, YASIR, A., W., WEBB, JOHN, R.
Applicants: CORIXA CORP, CORIXA CORPORATION
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, A61K39, C07K14, C12N1, C12N15